


DANIEL B. TIMMONS v. PURDUE PHARMA, L.P., et al.

Rule 26(a)(2) DISCLOSURE OF ARTHUR G. LIPMAN, PHARM.D.



I. NAME AND ADDRESS OF EXPERT

Arthur G. Lipman, Pharm. D., F.A.S.H.P.
College of Pharmacy, 30 S 200E RM 258
University of Utah
Salt Lake City, Utah 84112-5820

II. QUALIFICATIONS

1. I am the Director of Clinical Pharmacology at the Pain Management Center of the University of Utah Hospitals and Clinics. I am Professor of Pharmacotherapy in the College of Pharmacy and Adjunct Professor of Anesthesiology in the School of Medicine at the University of Utah. From 1977 to 1987, I was Chairman of the Department of Pharmacy Practice at the University of Utah.

2. I have been teaching coordinator at the University of Utah School of Medicine for Drug Therapy in Primary Care, from 1977 to the present.

3. I have extensive experience in clinical pharmacology, pain management, and symptom control in palliative care.

4. As Director of Clinical Pharmacology at the Pain Management Center, I work directly with chronic pain patients for whom I develop medication management regimens. I also counsel patients regarding the use of their medications. I am part of an interdisciplinary team of physicians, psychologists and physical therapists and regularly communicate with these professionals regarding patient status and treatment. I advise the treatment team



PKY183265978

members regarding medication management for the Center's patients, including recommendations regarding the prescribing of opioids.

5. During my career, I have been a board member of, or otherwise affiliated with many professional organizations, governmental agencies, and advisory boards. In 2003 I was an invited consultant to the U.S. Food and Drug Administration Advisory Committee on Anesthetic and Life-Saving Drugs on Opioid Risk Management. I was also a consultant to the U.S. Food and Drug Administration and National Institutes of Health on Analgesic Outcomes Studies in 2003, and to their Analgesic Drug Development Workshop in 2002. From 2000 to 2003, I was a member of the Pain Management Performance Measure Expert Panel of the Joint Commission on Accreditation of Healthcare Organizations. From 1996 to 1999, I was Chairman of the Vista Hospice Care Foundation National Advisory Board. Further examples of my work with these and other organizations can be found on my CV, attached as Exhibit A.

6. I have served as editor of the *Journal of Pain & Palliative Care Pharmacotherapy* 2002-present; *Journal of Pharmaceutical Care in Pain and Symptom Control* 1991 to 2001; *American Pain Society Bulletin*, Research Update Department, 1993 to 1995 and Palliative Care Department 2002-2004, and *Hospital Formulary* from 1979 to 1989. Additionally, I am a current and former editorial board member of 12 other professional and scientific journals.

7. I am author and editor of four books, over 100 articles, chapters and monographs, and over 350 reviews and editorials. A complete listing of my publications can be found on the attached curriculum vitae. I have been an invited lecturer at over 600 regional, national, and international professional and scientific meetings. I also have

participated in many research projects and clinical studies, both publicly and privately funded.

III. STATEMENT OF OPINION, BASIS, AND REASONS THEREFOR

8. Pharmacology is the study of how medications act on the body and what happens to medications in the body, termed the pharmacodynamics and pharmacokinetics of the medication. In my work, I focus primarily on the activity of pain medications including opioid analgesics.

9. Opioid analgesics produce pain relief by binding to receptors in the central nervous system and blocking the body's pain signals. OxyContin is a Schedule II Controlled Substance controlled release formulation of the opioid, oxycodone, which acts at the mu opioid receptors in the central nervous system.

10. There are various pharmacokinetic processes that affect the ability of a medication to produce pain relief. These include absorption, distribution, metabolism and elimination of the medication. *Absorption* refers to the processes that take place in the digestive tract for an oral opioid analgesic, such as OxyContin. Gastric fluids work on the medication to release and dissolve some of the active ingredient, oxycodone. During *distribution* the active ingredient is circulated throughout the body via the blood and as it circulates, some of it is *metabolized* by the body and some is deposited in various organs and fatty tissues. At the same time this is occurring, the body is *eliminating* some of the medication, just as it eliminates any foreign substance that is present.

11. The result of these various processes is that not all of the active ingredient in an opioid analgesic medication, such as the oxycodone in OxyContin, is able to reach the central nervous system where it produces the drug effect, pain relief.

12. OxyContin was specifically designed to provide both rapid onset and sustained pain relief in a continuous manner for its entire dosing schedule. Because OxyContin is not intended to be used as a PRN medication, but rather, around the clock for an extended period of time, the amount of initial release of the drug was designed to provide sufficient oxycodone in the plasma to provide a concentration gradient at the beginning of each dose to appropriately deliver oxycodone to the mu receptors and compensate for drug lost during metabolism and elimination.

13. The initial release of oxycodone from OxyContin does not create an unacceptably high peak level of oxycodone in the plasma. OxyContin was designed to provide efficient pain relief for patients requiring around-the-clock opioid therapy. I disagree with the statement in the Expert Disclosure of Dr. Stefan P. Kruszewski that "OxyContin has more in common with the addictive nature of a short-acting opioid than a long-acting opioid such as methadone, although it combines some of the most reinforcing and troublesome aspects of tolerance, withdrawal and dependence of both short and long acting opioids." The pharmacology of OxyContin does not support that claim. OxyContin provides initial pain relief and sustains it over 12 hours in most patients. OxyContin does not produce the same rapid peak as immediate release opioid dosage forms. OxyContin offers the advantage of less frequent dosing than immediate release oxycodone. Because OxyContin allows the patient to maintain a medication serum level over an extended period of time as compared to immediate release dosage forms, it does not produce the frequency of peak and valley effects

that occur with the immediate release formulations. This, it is not as reinforcing as short acting opioids.

14. Plasma concentration is different from the onset of drug effect. The Tmax (time to maximum plasma concentration) of OxyContin is typically 2-3 hours. The onset of effect is similar, but somewhat later and the Cmax (maximum plasma concentration) is slightly lower than that which occurs with immediate release opioids. OxyContin, if taken as directed, stays in the body producing effects longer than an immediate release medication. Most of the oxycodone is slowly and continuously released to provide sustained pain relief over the 12 hour dosing period. These unique and intentionally designed features of OxyContin distinguish it from the immediate release preparations and provide advantages for patients.

15. I also disagree with Dr. Kruszewski's statements that "Purdue provided dosing recommendations concerning OxyIR that were scientifically flawed" and that "Purdue provided inaccurate information about OxyContin and OxyIR dosing and drug kinetics." There are many clinical studies that support the 12 hour efficacy of OxyContin showing that, generally, this dosing schedule is effective in relieving patients' pain. Even so, physicians are aware that there is variability among patients and that dosing needs to be individualized for treatment. These studies include:

- ✓ Mandema JW, et al., **Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.** *Br J Clin Pharmacol* 1996, 42:747-756;
- ✓ Benziger D, et al., **A pharmacokinetic/pharmacodynamic study of controlled release oxycodone.** *J Pain Symptom Manage* 1997, 13:75-82;
- ✓ Kaplan R, et al., **Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.** *J Clin Oncol* 1998, 16: 3230-3237;

- ✓ Bruera, E., et al., Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. *J Clin Oncol* 1998, 16: 3222-3229;
- ✓ Hagen NA, Babul N, Comparative Clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. *Cancer* 1997, 79: 1428-1437;
- ✓ Kaiko RF, et al., Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. *Clin Pharmacol Ther* 1996, 59: 52-61;
- ✓ Reder RF, et al., Steady-state bioavailability of controlled release oxycodone in normal subjects. *Clin Ther* 1996, 18: 95-105;
- ✓ Mucci-LoRusso P, et al., Controlled release oxycodone compared with controlled release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. *Eur J Pain* 1998, 2:239-249;
- ✓ Citron ML, et al., Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. *Cancer Invest* 1998, 16:562-571.

16. Many of the clinical studies describe the use of rescue medication. In fact, OxyIR is used as a rescue medication. It is now the standard of practice to use rescue doses of a short acting opioid for breakthrough pain in conjunction with a long acting opioid preparation such as OxyContin. The clinical trials clearly demonstrate that there is not a significant diminution of pain relief in the last few hours of the OxyContin 12 hour span. The peaks and valleys of plasma oxycodone concentrations within the therapeutic window do not significantly affect pain relief being experienced by the patient. Breakthrough pain is part of the natural history of chronic pain and is well defined as such in the contemporary medical and scientific literature.

17. Dr. Kruszewski also makes the statement that the "conversion charts prepared by Purdue were misleading." The conversion charts are accurate, are based on clinical studies, and are not misleading. Physicians are aware that conversion charts are guidelines

based on population averages and are to be individualized for use with each patient in light of patient variability. Understood in that context, the conversion charts are useful and appropriate.

18. The litmus test for therapeutic effect and adverse effects is not the blood level of the drug, but the actual patient response. Pain and patients' tolerance for it are inherently individual. There is a broad therapeutic window in terms of plasma concentration and relatively small changes in this plasma concentration do not necessarily impact analgesia, mood effect, or adverse effects.

19. Most of the effects that Mr. Timmons describes as being caused by his use of OxyContin are effects that are not attributable to opioids, but may be attributable to other substances he was taking.

20. Pain has been and remains seriously under-treated in the United States. It is estimated that more than 500,000,000 Americans suffer from chronic pain. Even today, some terminal cancer patients suffer needlessly until their deaths. There have been intense efforts undertaken by federal and state agencies, national and state medical boards, professional organizations, medical and lay healthcare associations, accrediting agencies, and many others to highlight the problems of under-treated pain and suffering. For example:

- The Federation of State Medical Boards promulgated guidelines in 1998 for the use of opioid medication in the treatment of pain. Since then, many state medical boards have adopted these or similar guidelines or policies, in full or in part. The guidelines were recently refined as policy in May 2004 by the Federation of State Medical Boards.
- In 1999, the U.S. Department of Veteran's Affairs initiated a program and instructed nurses and physicians to treat pain as a "Fifth Vital Sign" and required them to routinely evaluate pain in every patient, regardless of diagnosis.

- The U.S. Department of Health and Human Services, through the Agency for Health Care Policy and Research (AHCPR), has promulgated clinical practice guidelines for the treatment of acute pain and cancer pain.
- Congress also declared the decade of 2001 to 2010 to be the "Decade of Pain Control and Research" in H.R. 3244, Title VI, Sec. 1603. The stated purpose was to correct a lack of emphasis on pain at the federal level "resulting in a lack of investment in research, education and treatment" of pain.
- The California Medical Board now requires a one-time, 12 hour continuing medical education program on pain management as a condition of licensure and re-licensure. Unfortunately, California is the only state so far to have formalized a pain management requirement for practicing physicians.
- Evidence-based clinical practice guidelines on the management of a range of pain types have been published in recent years by several respected professional organizations including the American Pain Society, the American College of Rheumatology, and American Geriatrics Society.

21. The general absence of medical board mandates for pain management education makes it essential to explore all possible avenues to provide this instruction to practicing physicians, pharmacists, and nurses.

22. A primary benefit of pharmaceutical company educational programs is the education of healthcare professionals as to the nature and management of the conditions for which their drugs are marketed and the appropriate use of their products for those conditions.

23. These educational efforts take many forms, from printed "leave behind" materials to formal programs for which continuing medical education (CME) credits are awarded. Before a program can be awarded CME status, its content must be analyzed to ensure that it meets the requirements of the Accreditation Council on Continuing Medical Education (ACCME).

IV. DATA AND OTHER INFORMATION CONSIDERED IN FORMING THE ABOVE OPINIONS

24. My opinions are based on my experience, background, and training in pharmacology and the scientific and medical literature available to pharmacists and physicians relating to pain management. In addition, I have reviewed the following materials in this case: medical records for the plaintiff, plaintiff's expert disclosures, deposition testimony of the plaintiff, and the amended complaint as well as other relevant materials including the clinical studies cited in this report.

V. EXHIBITS TO BE USED TO SUMMARIZE OR SUPPORT OPINIONS

25. Some demonstrative exhibits or charts may be used to summarize my opinions or their bases. These demonstrative exhibits or charts are not yet available, and will be submitted at a later time, as agreed upon by the parties or ordered by the Court.

VI. LIST OF PUBLICATIONS AUTHORED BY EXPERT WITHIN THE PAST TEN YEARS

26. Please refer to my curriculum vitae, a copy of which is attached as Exhibit A.

VII. COMPENSATION TO BE PAID TO EXPERT FOR CASE REVIEW, OPINIONS, TESTIMONY, AND OTHER WORK ON THE CASE.


27. I am reimbursed at the rate of \$350.00 per hour for his consultation and testimony time.

VIII. LIST OF CASES IN WHICH EXPERT HAS TESTIFIED AS AN EXPERT, EITHER AT TRIAL OR BY DEPOSITION WITHIN THE PAST FOUR YEARS


28. In the past four years, I may have provided deposition or trial testimony in between 4 to 12 instances. I do not maintain any regular listing of such matters. Upon request from counsel, I will attempt to reconstruct such a list.

I reserve the right to supplement this disclosure based upon additional discovery not yet concluded. I may have further opinions based upon additional information obtained through disclosures, depositions, or other means, including rebuttal or additional allegations or theories raised by plaintiffs.

Dated this 20th day of June, 2005



Arthur G. Lipman, Pharm.D.



P. Marion Lenberg
Signed before me on
June 20, 2005.

CURRICULUM VITAE

Arthur G. Lipman, Pharm.D.

Professor
Department of Pharmacy Practice
College of Pharmacy, University of Utah
Salt Lake City, Utah 84112

Telephone: (801) 581-5986
Fax: (801) 585-6160
Email: alipman@pharm.utah.edu

Home Address: 6281 South Havenbrook Circle, Salt Lake City, Utah 84121

Birthplace: New Bedford, Massachusetts

EDUCATION

Bachelor of Science (Pharmacy)
University of Rhode Island
Kingston, Rhode Island

Doctor of Pharmacy 1968
University of Michigan
Ann Arbor, Michigan

PERSONAL

Married to Patrice M. Arent, J.D.
2 children: Sarah and Joshua

HONORS

Distinguished Service Award, American Alliance of Cancer Pain Initiatives, 2001.
Award for Sustained Contributions to the Literature of Pharmacy in Health Systems, American Society of Health Systems Pharmacists Research & Education Foundation, 1999
Hospice Pioneer Award, Utah Hospice Organization, 1999
Fellow, American Society of Health-System Pharmacists, 1996
National Hospice Organization - Clinical Care Giver Heart of Hospice Award, 1994
Saint George Medal - American Cancer Society National Divisional Award, 1993
Merrell Dow Lectureship in Clinical Pharmacy, University of Manchester, Manchester, England, 1990
Rho Chi, Pharmaceutical Honor Society
Outstanding Teacher of the Year Award, Physicians Assistant Program, University of Utah School of Medicine, 1988
P.G. Pierpaoli Lecture Award, Connecticut Society of Hospital Pharmacists, 1981
American Society of Hospital Pharmacists Research & Education Foundation Award for Achievement in Professional Practice, 1980
Didactic Instructor Award, Jack Cole Society, Yale University School of Medicine, 1978
Certificate of Special Recognition, Physicians Associate Program, Yale University School of Medicine, 1975
Connecticut Hospital Pharmacist of the Year Award, 1974
Squibb Past Presidents Award, Connecticut Society of Hospital Pharmacists, 1974
Geigy Leadership Award, Connecticut Society of Hospital Pharmacists, 1974
Lundsford-Richardson National Pharmacy Undergraduate Research Award, 1967
McKesson and Robins Pharmacy Administration Award, University of Rhode Island, 1967
Kappa Psi Pharmaceutical Fraternity Scholarship Honors, 1966-1967, 1965-1966

ACADEMIC APPOINTMENTS

1987-present Professor, Department of Pharmacotherapy, College of Pharmacy, University of Utah
Adjunct Professor, Department of Anesthesiology, School of Medicine, University of Utah
1982-1987 Professor of Clinical Pharmacy and Chairman, Department of Pharmacy Practice, University of Utah
1977-1982 Associate Professor of Clinical Pharmacy and Chairman, Department of Pharmacy Practice, University of Utah
1977 Associate Clinical Professor of Pharmacy, University of Connecticut School of Pharmacy
1974-1977 Lecturer in Community Health Nursing, Yale University Graduate School of Nursing
-1977 Assistant Clinical Professor of Pharmacy, University of Connecticut School of Pharmacy
1971-1977 Lecturer in Surgery, Yale University School of Medicine

TEACHING COORDINATOR POSITIONS

PKY183265988

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER
IN COMMONWEALTH OF KENTUCKY, EX REL. JACK CONWAY, ATTORNEY GENERAL v. PURDUE PHARMA L.P., ET AL.,
CIVIL ACTION NO. 07-CI-OI 303 (PIKE COUNTY CIRCUIT COURT)

P-27120 _ 00011

1977-present Drug Therapy in Primary Care
School of Medicine, Physicians Assistant Program, University of Utah
1976-1977 Non-credit Extension Program
Fairfield University, Fairfield, CT
1974-1977 Clinical Pharmacology
Clinical Nurse Practitioner Program, Yale University School of Nursing
1972-1975 Pharmacology for Inhalation Therapists
Yale-New Haven Hospital School of Inhalation Therapy
1971-1977 Medication Nurse Course
Yale-New Haven Hospital
1971-1977 Nursing Inservice Education in Drug Therapy
Yale-New Haven Hospital
1970-1977 Clinical Pharmacology and Therapeutics
Physician's Associate Program, Yale University School of Medicine
1969-1970 Medication Nurse Course
U.S. Public Health Service Indian Hospital, Tuba City, Arizona

PROFESSIONAL EXPERIENCE

1984-present Director of Clinical Pharmacology
Pain Management Center
University of Utah Hospitals and Clinics
1989 (While on Sabbatical leave from the University of Utah)
April-June, Research on the development of a cancer pain data system, Sir Michael Sobell House,
Churchill Hospital
University of Oxford, England
1989 (While on Sabbatical leave from the University of Utah)
February-April Active Duty, U.S. Public Health Service
Special Projects, Consultation to the Office of the Assistant Surgeon General
1977-1987 Coordinator of Pharmaceutical Services
University of Utah Health Sciences Center
1973-1977 Drug Information Director and Associate Director of Pharmacy Services
Yale-New Haven Hospital
New Haven, Connecticut
1970-1973 Drug Information Director
Department of Pharmacy Services
Yale-New Haven Hospital
New Haven, Connecticut
1968-1970 Commissioned Officer
United States Public Health Service, Active Duty
1967 Community Pharmacist
New Bedford, Massachusetts
1966-1967 Pharmacy Intern
New Bedford, Massachusetts
1965-1966 Field Auditor
National Prescription Audit

PHARMACIST LICENSURE

Massachusetts, by examination, 1967, No. 14809
Utah, by reciprocity, No. 3137
Connecticut, 1970-1995

Rhode Island, by examination, 1967, No. 1851
New Hampshire, 1983 (honorary)

PUBLICATIONS

Books

- Drug Use in Assisted Suicide and Euthanasia. MP Battin and AG Lipman, editors, Binghamton NY, Haworth Press, 1996.
- Evidence-Based Symptom Control in Palliative Care. AG Lipman, LS Tyler and KC Jackson, editors, Binghamton NY, Haworth Press, 2000.

Chapters and Monographs

1. Lipman AG. Monitoring and recording drug interactions, in Drug Interactions, University of Connecticut, 1972.
2. Lipman AG. Establishing a drug information service, Hospital Pharmacy Notes, Eli Lilly and Co., Indianapolis, IN, 1974.
3. Lipman AG. Drug therapy in terminally ill patients, Clinical Pharmacy Sourcebook, American Society of Hospital Pharmacists, Publishing Sciences Group, Acton, MA, 1976.
4. Lipman AG, Decker EL. Therapeutics: H₂ Receptor Antagonists in Peptic Ulcer Disease, Biomedical Information Corporation, New York, 1978.
5. Lipman AG, Molde S. Drug therapy in infectious disease, in Pharmacology and Therapeutics for Nurses, Weiner, Pepper and Romano (eds), McGraw Hill, New York, 1979.
6. Lipman AG. Interactions between diet and drugs, in Handbook of Clinical Dietetics, American Dietetic Association, Yale University Press, New Haven and London, 1980.
7. Lipman AG. Antimicrobial agents, in Pharmacology for the Dental Hygienist, Lewis, Lewis and Mackowiack (eds), Science Research Associates, Chicago, 1980.
8. Anderson J, Freeman HP, Gross SM, Humma KG, Lemberger AP, Leone LA, Lipman AG, Oppenheimer S, Roberts RW, Youngken HW. The Role of the Pharmacist in Cancer Management: Curriculum Guide and Role Definition, American Cancer Society, New York, 1980.
9. Lipman AG. Drug therapy in terminally ill patients, Source Book on Clinical Pharmacy, PSG Publishing Group, Littleton, MA, 1980.
10. Lipman AG. Drugs in pain and symptom management, in Hospice - A Unique Nursing Opportunity, DHEW, USPHS, Health Resources Administration, Division of Nursing, Government Printing Office, Washington, DC, 1981.
11. Lipman AG. On drug and food interactions, Executive Health Report, 18(2), November 1981.
12. Lipman AG. Drug therapy in cancer pain, in Dying Persons and Hospice, Corr CA and Corr DN (eds), Springer Publishing Co., New York, 1982.
13. Lipman AG. Management of pain, in Geriatric Curriculum, American Association of Colleges of Pharmacy, Health Sciences Consortium, Chapel Hill, NC, 1984.
14. Lipman AG. Pain management, in Clinical Pharmacy and Therapeutics, Herfindal CT and Hirschmann JR (eds), 3rd Edition, Williams and Wilkins, Baltimore, 1984.
15. Lipman AG, Mooney KG. Management of pain, in Clinical Pharmacology and Therapeutics in Nursing, 2nd Edition, Weiner M and Pepper G (eds), McGraw Hill, New York, 1985.
16. Lipman AG. Decentralized pharmacy systems for drug use control, in Pharmacy Practice - The Year 2000, Moore RL (ed), Pan Pacific Foundation - United States, Greensboro, NC, 1985.
17. Lipman AG. Formulary development, in Institutional Pharmacy Management, Wertheimer A and Daniels C (eds), Pan American Health Organization, 1988.
18. Lipman AG. Barriers to the development of clinical practice in pharmacy, in the Report of the Western Regional Conference on Clinical Pharmacy Practice, Coto De Caza, CA, 1987.
19. Lipman AG. Newer findings in the pharmacology of opioid analgesics. Norwich-Eaton Pharmaceuticals, 1988.
20. Lipman AG. Pain management. Wellcome Programs in Hospital Pharmacy, Burroughs Wellcome Co., 1988.
21. Hare BD, Lipman AG. Uses and Misuses of Medication in the Treatment of Chronic Pain. In Hare BD, Fine P (editors), Chronic Pain, Problems in Anesthesia, Philadelphia, JB Lippincott Co., 1990
22. Lipman AG. Pharmacy Services in Hospice. Wellcome Trends in Hospital Pharmacy, New York, Health Education Technologies, June 1990.
23. Lipman AG. Drug-Use Management, in Handbook of Institutional Pharmacy Practice, 3rd edition, Brown TR, Smith MC, editors. Bethesda, American Society of Hospital Pharmacists, 1992.

-continued-

Chapters and Monographs (continued)

25. Acute Pain Management Guideline Panel. Acute Pain Management: Operative or Medical Procedures and Trauma,

PKY183265990

- Clinical Practice Guideline. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, Feb. 1992.
26. Acute Pain Management Guideline Panel. Acute Pain Management in Adults: Operative Procedures. Quick Reference Guide for Clinicians. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1992.
27. Acute Pain Management Guideline Panel. Acute Pain Management in Infants, Children and Adolescents: Operative and Medical Procedures. Quick Reference Guide for Clinicians. AHCPR Pub. No.92-0020. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1992.
28. Acute Pain Management Guideline Panel. Pain Control After Surgery. A Patient's Guide. AHCPR Pub. No.92-0021. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1992.
29. Lipman AG. Curriculum on Pain for Pharmacy Students. International Association for the Study of Pain Newsletter. 1992;May/June:2-4.
30. Lipman AG. Pharmacist involvement and Drug Therapy Issues in State Cancer Pain Initiatives. American Pain Society Bulletin. 1992(Oct/Nov):16,22.
31. Lipman AG. Use of medications in the treatment of pain and injury, in The Psychology of Sport Injury, Heil J (ed), Champagne IL, Human Kinetics Press, 1993.
32. Lipman AG. Current Issues in Pain Management. Syntex Laboratories, 1994.
33. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline. Rockville MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
34. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Adult Quick Reference Guide. Rockville MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
35. Jacox A, Carr DB, Payne R, et al. Managing Cancer Pain. Patient Guide. Rockville MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
36. Lipman AG, Reisner-Keller LA. The Use of Opioids in Chronic, Non-Malignant Pain, Controversies, Pain Management Pharmacy Newsletter 1994;1(1).
37. Lipman AG and Berry JI. Pharmaceutical Care of Terminally Ill Patients. in Social and Behavioral Aspects of Pharmaceutical Care. Smith M and Wertheimer A (editors), Binghamton NY, Haworth Press, 1996.
38. Lipman AG and Gauthier ME. Pharmacology of Opioid Drugs: Basic Principles. In Topics in Palliative Care: Advances in the Pharmacotherapy of Pain. Portenoy R, Bruerea E. (Editors), New York, Oxford University Press, 1996.
39. Lipman AG. Internal analgesic and antipyretic products. In Handbook of Nonprescription Drugs, 11th edition, Washington DC, American Pharmaceutical Association, 1996.
40. Lipman AG. Pharmaceutical Care of the Acute Pain Patient. GlaxoWellcome Trends in Pharmacy, Helix Online (World Wide Web), <http://www.helix.com/member/mbrhome.html> 1996
41. Lipman AG. Pharmacological Approaches to Pain Management: Nontraditional Analgesics and Analgesic Adjuvants. In Ashburn MA, Rice LF, editors, The Management of Pain. New York, New York, Churchill Livingstone 1997.
42. Lipman AG. Pharmacology of Opioids: Basic Principles. In Portenoy RK, Bruera E, editors, Topics in Palliative Care. New York, Oxford University Press, 1997.
43. Lipman AG, Jackson KC. Headache, Muscle and Joint Pain. in Handbook of Nonprescription Drugs, 12th edition, Washington DC, American Pharmaceutical Association, 2000.
44. Lipman AG, Jackson KC. Fever. in Handbook of Nonprescription Drugs, 12th edition, Washington DC, American Pharmaceutical Association, 2000.
45. Lipman AG, Jackson KC. Use of opioids in chronic noncancer pain. New York, Power-Pak Communications, 2000.
46. Lipman AG, Jackson KC. Opioids. In Warfield C, Bajwa Z, editors, Principles and Practice of Pain Management, 2nd edition, New York, McGraw Hill, 2002.
47. Jackson KC, Lipman AG Opioid Analgesics. In Tollison D, editor, Clinical Pain Management: A Practical Approach, 3rd Edition, Philadelphia, Lippincott - Williams & Wilkins, 2002.
48. Simon L, Lipman AG, Jacox A et al. Guideline for the Management of Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis Pain. Glenview IL, American Pain Society, 2002.

Articles in Refereed Journals

1. Lipman AG, Osborne GE. Medicine and pharmacy aboard New England whaling vessels: the captain, an apothecary-surgeon at sea. *Pharm in Hist* 1969;11:119-131.
2. Lipman AG. Child-resistant medication containers to reduce pediatric drug poisonings. *Conn Med* 1972;38:666-668.
3. Beste DF, McCart GM, Lipman AG. New services generate teaching role. *Hospitals, JAHA* 1973;4:141-146.
4. Lipman AG, Corrison W, Westerman J. Practalol - foreign drug evaluation. *Hosp Pharm* 1973;8:315-322.
5. Lipman AG, Mullen HF. Quality control for pharmaceutical industry representatives. *Amer J Hosp Pharm* 1974;31:167-70.
6. Lipman AG. The effect of buffering on the incidence and severity of cephalothin induced phlebitis. *Amer J Hosp Pharm* 1974;31:266-268.
7. Lipman AG. Drug therapy in terminally ill patients. *Amer J Hosp Pharm* 1975;32:270-276.
8. Lipman AG, Brooks KJ. Clinical considerations in analgesic therapy: narcotic analgesics. *The PA Journ* 1976;6:68-71.
9. Lipman AG, Bauer E. Pharmaceutical group purchasing cuts costs, expands knowledge. *Hospitals, JAHA* 1976;50:99-104.
10. Lipman AG, Brooks KJ. Clinical considerations in analgesic therapy: non-narcotic analgesics. *The PA Journ* 1976;6:21-4.
11. Kern J, Lipman AG. Rational theophylline therapy: a review of the literature with guide to pharmacokinetics and dosage calculation. *Drug Intell Clin Pharm* 1977;11:144-153.
12. Bennett BS, Lipman AG. A comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. *Amer J Hosp Pharm* 1977;34:931-936.
13. Lipman AG, Madeux B. Computer based formulary service reduces costs, eliminates confusion. *Hospitals, JAHA* 1977;51:109-112.
14. Ponte CD, Lipman AG, Moran CP. Utilization review of nutritionally complete liquid diets. *Amer J Hosp Pharm* 1978;35:159-162.
15. Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR. An algorithm for the assessment of adverse drug reactions. *JAMA* 1979;242:633-635.
16. Lipman AG, McMahon JD. The development of program guidelines for community and institutional externships. *Am J Pharm Ed* 1979;43:217-223.
17. Lipman AG, Devenport JK. An integrated, competency based curriculum for doctor of pharmacy students. *Am J Pharm Ed* 1979;43:214-216.
18. Lipman AG, Bair JN, Hibbard FJ, et al. Decentralization of pharmacy services without satellite pharmacies. *Amer J Hosp Pharm* 1979;36:1513-1519.
19. Lipman AG. Drug therapy in chronic pain. *J Cont Ed Clin Hosp Pharm* 1979;1:5:10-22.
20. Lipman AG. Drug therapy in cancer pain. *Cancer Nurs* 1980;3:39-46.
21. Russo J Jr, Lipman AG, Comstock TJ, Page BC, Stephen RL. Lidocaine anesthesia: comparison of iontophoresis, injection, and swabbing. *Amer J Hosp Pharm* 1980;37:843-847.
22. Lipman AG, Bair JN. A graduate program in institutional pharmacy management leading to an MS in hospital pharmacy, MBA and residency. *Am J Pharm Ed* 1981;45:17-20.
23. Phillips RC, Lipman AG. Physician perceptions of clinical pharmacy service. *Hosp Formul* 1981;16:996-1009.
24. Lipman AG, Devenport JK, Page BC. An analysis of information provided by clinical pharmacists. *Amer J Hosp Pharm* 1982;39:71-73.
25. Superstine E, Lipman AG, Bair JN, Baum S. Considerations in selecting a mobile master medication cart. *Amer J Hosp Pharm* 1983;40:293-294.
26. Lipman AG. Motivating faculty. *Am J Pharm Ed* 1983;47:364-366.
27. Lipman AG. Formulary system controversies in the new environment of DRGs. *Hosp Formul* 1985;20:218-232.
28. Yosselson-Superstine S, Lipman AG, Sanders SH. Adjunctive artianxiety agents in the management of chronic pain. *Isr J Med Sci* 1985;21:113-117.
29. Lipman AG. Integrating clinical and distributive pharmaceutical services: implications for clinical pharmaceutical education. *Am J Pharm Ed* 1986;50:63-66.
30. Lipman AG. Drug therapy considerations in the renally compromised geriatric patient. *The Consultant Pharmacist* 1987;2(Suppl B):8-11.
31. Kleiman RL, Lipman AG, Hare BD, MacDonald SD. A comparison of morphine administered by patient-controlled analgesia and regularly scheduled intramuscular injection in severe postoperative pain. *J Pain Symp Manage* 1988;3:15-22.
32. Lipman AG. Documenting Hospice. *American J Hospice Care* 1988;5.
33. Lipman AG. Newer findings in the pharmacology of opiate analgesics. *Contemp Surg* 1988; 33 (Suppl 3A):6-12.
34. Lipman AG. Opioid analgesics in the management of cancer pain: pharmacokinetic considerations. *Am J Hospice Care* 1988;6:(1) 13-28.

-continued-

PKY183265992

Articles in Refereed Journals (continued)

35. Lipman AG. Current information on the use of immunobiologics: comments of the ASHP Commission on Therapeutics. *Clin Pharm* 1989;8:850-851.
36. Lipman AG. Drug therapy in the management of pain. *Br J Pharm Practice*. 1990;12:22-29.
37. Lipman AG. Pain management in the home care and hospice patient. *J Pharm Practice*. 1990;3:1-11.
38. Arter SG, Lipman AG. Hospice Care: a new opportunity for pharmacists. *J Pharm Practice*. 1990;3:28-33.
39. Lipman AG. Clinical advances in the management of pain. *The IHS Primary Care Provider*. 1990;15:54-61.
40. Lipman AG. Clinically relevant differences among the opioid analgesics. *Clin Pharm*. 1990;47(Suppl 1):S7-13.
41. Lipman AG. Specialization in pharmacy education: resources and risks. *Am J Pharm Ed.*; 1990;54:381-382.
42. Lipman AG. Opioid use in the treatment of pain: Refuting 10 common myths. *Pain Management*. 1991;4(4):13-17.
43. Ashburn MA, Lipman AG. Management of Pain in the Cancer Patient. *Anesth Analg*. 1993;76:402-416.
44. Kerrick JM, Fine PG, Lipman AG, Love G. Low-dose amitriptyline as an adjunct to opioids for post-operative orthopedic pain: a placebo-controlled trial. *Pain* 1993;52:325-330.
45. Lipman AG. The argument against therapeutic use of heroin in pain management. *Am J Hosp Pharm*. 1993;50:996-998.
46. Lipman AG. Rational and cost-effective NSAID therapy. *J Pharm Care Pain Symptom Control*. 1994;2(2):39-46.
47. Lipman AG, Berry JJ. Pharmaceutical care of terminally ill patients. *J Pharm Care Pain Symptom Control*. 1995;3(2): 31-56.
48. Battin MP, Lipman AG. The need to objectively examine issues in assisted suicide and euthanasia. *J Pharm Care Pain Symptom Control* 1995; 3(3-4): 1-10.
49. Lipman AG. Pharmaceutical Care of The Acute Pain Patient. *Trends in Pharmacy Online*. 1996:December.
50. Lipman AG. Analgesic drugs for neuropathic and sympathetically maintained pain. *Clinics in Geriatric Medicine* 1996;12:501-515.
51. Lipman AG. Pharmacologic approaches to neuropathic pain. *Current Review of Pain* 1997;1:285-295.
52. Doucette WR, Mays-Holland T, Memmott H, Lipman AG. Cancer pain management: pharmacist knowledge and practices. *J Pharm Care Pain Symptom Control* 1997;5(3):17-32.
53. Lipman AG. Pain management in a patient with medication allergy. *Cancer Practice* 1998;6:8-10.
54. Lipman AG. Methadone in the management of pain in cancer patients reviewed. *Oncology* 1999;13:1285-8.
55. Lipman AG. The role of the pharmacist in palliative care. *Trends in Pharmacy Online*. 2000:in press.
56. Lipman AG. Evidence-based palliative care. *J Pharm Care Pain Symptom Control* 1999;7(4):1-10.
57. Tyler LS, Lipman AG. Anorexia and cachexia in palliative care patients. *J Pharm Care Pain Symptom Control* 1999;7(4):11-22.
58. Jackson KC, Lipman AG. Anxiety in palliative care patients. *J Pharm Care Pain Symptom Control* 1999;7(4):23-36.
59. Jackson KC, Lipman AG. Delirium in palliative care patients. *J Pharm Care Pain Symptom Control* 1999;7(4):59-70.
60. Tyler LS, Lipman AG. Fatigue in palliative care patients. *J Pharm Care Pain Symptom Control* 2000;8(1):129-142.
61. Ferrell BR, Novy D, Sullivan MD, Banja J, Lipman AG et al. Ethical dilemmas in pain management. *J Pain*. 2001; 2:171-80.
62. Lipman AG. Treatment of chronic pain in osteoarthritis: do opioids have a role? *Current Rheumatol Reports*. 2001;3:513-19.
63. Macario A, Lipman AG. Ketorolac In The Era of COX-2 Inhibitors: Update On Efficacy, Side Effects, and Regulatory Issues *Pain Med*. 2001;2:336-51
64. Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. *J Pain* 2002;3: 159-180.
65. Oderda, Evans RS, Lloyd J, Lipman AG, Chen C, Ashburn MA, Burke J, Samore M. Cost of opioid-related adverse events in surgical patients. *J Pain Symptom Manage* 2003;23:64-73.
66. Fakata KL, Lipman AG. Pharmacotherapy for pain in rheumatologic conditions: the neuropathic component. *Curr Pain Headache Rep*. 2003;7: 197-205.

PKY183265993

Abstracts

1. Lipman AG, Osborne GE. Medicine and pharmacy aboard New England whaling vessels, I: the captain, an apothecary-surgeon at sea. American Institute of the History of Pharmacy, Abstracts of the 113th Annual Meeting, American Pharmaceutical Association, Dallas, TX, 1966.
 2. McCart GM, Lipman AG, Beste DF. The care of the dying patient - an interdisciplinary approach. Abstracts of the 6th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, 1971.
 3. Lipman AG, Deffenbaugh JH Jr. The patient health record: a major means for improving outpatient pharmacy services. Abstracts of the 7th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, 1972.
 4. Lipman AG. The effect of buffering on cephalothin induced phlebitis. Abstracts of the 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, 1973.
 5. Lipman AG. Providing quality control of pharmaceutical industry representative activities within the institution. Abstracts of the 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, 1973.
 6. Lipman AG, Greenberg BR. Drug literature abstract and index services. Abstracts of the 31st Annual Meeting, American Society of Hospital Pharmacists, Chicago, IL, 1974.
 7. Rubino MJ, Lipman AG. Critical comparisons of commonly available iodophor solutions and scrubs. Abstracts of the 31st Annual Meeting, American Society of Hospital Pharmacists, Chicago, IL, 1974.
 8. Decker EL, Lipman AG, Cote J. The effect of in-line filtration on the incidence and severity of cephalothin-induced infusion phlebitis. Abstracts of the 10th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, 1975.
 9. Vengrofski AM, Lipman AG, Miller RF. Utilization review of normal serum albumin. Abstracts of the 11th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1976.
 10. Bennett BS, Lipman AG. A comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. Abstracts of the 11th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1976.
 11. Ponte CD, Lipman AG. Utilization review of nutritionally complete oral liquid diets. Abstracts of the 11th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1976.
 12. Lipman AG, McMahon JD. The development of an auxiliary faculty of practicing pharmacist role models for the provision of meaningful community and hospital general practice externships. Abstracts of the 79th Annual Meeting, American Association of Colleges of Pharmacy, Orlando, FL, 1978.
 13. Lipman AG, Devenport JK. An integrated, competency based, clinical curriculum for doctor of pharmacy students. Abstracts of the 79th Annual Meeting, American Association of Colleges of Pharmacy, Orlando, FL, 1978.
 14. Lipman AG, Bair JN, Russo J Jr. Planning for decentralization of pharmacy services. Abstracts of the 13th Midyear Clinical Meeting, American Society of Hospital Pharmacists, San Antonio, TX, 1978.
 15. Lipman AG. Medicine and pharmacy aboard New England whaling vessels, II: drugs used, their indications, applications, sources and costs. American Institute of the History of Pharmacy, Abstracts of the 126th Annual Meeting, American Pharmaceutical Association, Anaheim, CA, 1979.
 16. Lipman AG, Devenport JK, Page B. A multidimensional study of clinical pharmacist process. Abstracts of the 37th Annual Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1979.
 17. Lipman AG, Bair JN. Experience with a graduate program in institutional pharmacy management leading to an M.S. in hospital pharmacy, M.B.A. and residency. Abstracts of the 80th Annual Meeting, American Association of Colleges of Pharmacy, Denver, CO, 1979.
 18. Russo J Jr, Lipman AG, Page B, Stephen R. Iontophoresis of lidocaine for topical anesthesia. Abstracts of the 14th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, 1979.
 19. Lipman AG, Wolf HH. A postdoctoral fellowship program for faculty development in clinical pharmacy. Abstracts of the 81st Annual Meeting, American Association of Colleges of Pharmacy, Boston, MA, 1980.
 20. Lipman AG, Bair JN, Gisclon LG. Implementation of a comprehensive quality assurance program for pharmaceutical services. Abstracts of the 15th Midyear Clinical Meeting, American Society of Hospital Pharmacists, San Francisco, CA, 1980.
 21. Lipman AG, Higbee MD, Devenport JK. Education and service directed toward meeting the needs of the elderly. Abstracts of the 82nd Annual Meeting, American Association of Colleges of Pharmacy, Scottsdale, AZ, 1981.
 22. Lipman AG. Drug therapy for symptom control in terminal disease. Abstracts of the 148th National Meeting of the American Association for the Advancement of Science, Washington, DC, 1982.
- Kleiman R, Lipman A, Hare B. Controlled study of patient controlled analgesia in severe, post-operative pain. Pain 1984;20(Suppl 2):387.

-continued-

PKY183265994

P-27120 _ 00017

Abstracts - continued

25. Zbrozek AS, Sudds TW, Bair JN, Lipman AG. Development and marketing of a drug studies pharmacist position. Abstracts of the 43rd Annual Meeting, American Society of Hospital Pharmacists, Denver, CO, 1986.
26. Lipman AG. The formulary review process in the current fiscal environment. Abstracts of the 45th Annual Meeting, American Society of Hospital Pharmacists, San Francisco, CA, 1988.
27. Lipman AG, Czajkowski LA. Pharmacological and psychological considerations in the management of prostatic cancer pain. Abstracts of the Western USA Pain Society Annual Meeting, Santa Fe, NM, 1988.
28. Church RM, Lipman AG, Herrier RN, Smith EB, Boyce RW, Dwight V. Development and implementation of standards of practice for a multiple institution system of hospitals and ambulatory care centers. Abstracts of the 24th ASHP Midyear Clinical Meeting, American Society of Hospital Pharmacists, Atlanta, Georgia, 1989.
29. Lipman AG. Process and outcomes of comprehensive medication histories in chronic pain patients. Abstracts of the Western USA Pain Society Annual Meeting, Park City, UT, 1990.
30. Lipman AG, Twycross RG, Cleeland C, Johns S. A system for concurrent data collection and retrospective analysis of advanced cancer pain and its management. *Pain* 1990;Suppl 5:S374.
31. Lipman AG, Berri JJ. Role of the Hospice Pharmacist. Abstracts of the 139th Annual Meeting, American Pharmaceutical Association, San Diego, California, 1992.
32. Lipman AG. New Directions in Pain Management. *International Pharmaceutical Abstracts*. 1993;30:1145.
33. Lipman AG. The cornerstone of the team approach: a case for better pain management. *American Academy of Physician Assistants Annual Conference Abstracts*, 1995.
34. Lipman AG. Adjunctive analgesic drugs in the elderly. Abstracts of the American Society of Consultant Pharmacists Annual Meeting 1995 Educational Sessions, 1995:97.
35. Lipman AG. Pain management: pharmacoeconomic and clinical outcomes. Abstracts of the Academy of Managed Care Pharmacy Annual Meeting, 1996.
36. Lipman AG. Evidence-based drug therapy symptom control guidelines for palliative care. *J Pain Symptom Manage* 1998;15:S:5.
37. Lipman AG. Cancer Pain Management: Pharmacist Knowledge and Practices. *American Pain Society 1998 Annual Meeting Program*:613.
38. Lipman AG, Tyler LS, Jackson II KC. Evidence-based, Drug Therapy Symptom Control Guidelines for Palliative Care. *J Palliative Med*. 1999;2:247
39. Jacobson JA, Lipman AG, Beck SL. A Successful Statewide Collaboration to Improve End of Life Care. *J Palliative Med*. 1999;2:252.
40. Oderda GM, Evans RS, Lloyd J, Lipman AG, Ashburn MA, Chen C, Burke J, Samore M. Cost of opioid related adverse drug events in surgical patients. *International Pharm Abstr*. 2001; 38(21):37.
41. Lipman AG, Dalpiaz A, Lorden SP. Topical lidocaine patch therapy for myofascial pain. *J Pain* 2002;3(2)(Suppl1):46

Editorials

1. Lipman AG. Clinical pharmacy: specialty or norm. Hospital Pharmacy 1974;9:257.
2. Lipman AG. Concern for dying patients. American Journal of Hospital Pharmacy 1974;32:368.
3. Lipman AG. Hospital Formulary 1979;14
4. Open versus closed formularies: Cost-benefit considerations, March p. 380.
5. A broadened base, July, p. 728.
6. An ounce of protection, August, p. 788.
7. Predetermined standards in use of drug control, September, p. 864.
8. Clinical pharmacokinetics and improved drug therapy, October, p. 948.
9. Congratulations Jere Goyan-the first pharmacist to be FDA commissioner, November, p. 1016.
10. Intravenous infusion pumps: A P&T committee concern, November, p. 1015.
11. Patients' perspective on nonprescription drugs, December, p. 1076.
12. Lipman AG. Hospital Formulary 1980;15
13. Why a refereed journal? January, p. 66.
14. Therapeutic devices and the P&T committee, February, p. 152.
15. The Hospital Formulary research award: Recognition of excellence, March, p. 228.
16. Debunking some myths about chronic pain therapy, April, p. 328.
17. Letters: A forum for controversies and reports, May, p. 426.
18. Hospital Formulary experience briefs: Another opportunity to share, June, p. 508.
19. Adverse drug reactions and the P&T committee, July, p. 580.
20. From pharmacy department to department of pharmacy services, August, p. 646.
21. Alimentation and hyperalimentation formulae: Drugs or diets, September, p. 724.
22. P&T and IRB: A need for effective communications, October, p. 812.
23. Clinical pharmacy: An evolution, November, p. 914.
24. Our name and our change, December, p. 986.
25. Lipman AG. Hospital Formulary 1981;16
26. A reaffirmed focus, January, p. 9.
27. Fiscal responsibility and patient care, February, p. 105.
28. Repetition need not be merely redundant, March, p. 239.
29. Collaboration for improved patient care and decreased drug costs, April, p. 371.
30. Hypertension revisited, May, p. 475.
31. What are we doing with our poisons? June, p. 577.
32. Our orphaned outpatients, July, p. 697.
33. The growing menace of drug abuse, August, p. 797.
34. Clinical pharmacy: physicians' friend or foe?, September, p. 923.
35. Rational antimicrobial therapy, October, p. 1105.
36. An international flavor, November, p. 1259.
37. Our biggest and our best, December, p. 1405.
38. Lipman AG. Hospital Formulary 1982;17
39. Nutritional therapeutics: A P&T committee concern, January, p. 9.
40. Drug information for patients, February, p. 185.
41. An award for safety, March, p. 359.
42. Prophylactic antibiotics, April, p. 503.
43. Consultation in clinical psychopharmacology, May, p. 649.
44. Lipman AG. Hospital Formulary 1982;17
45. The acceptance of clinical pharmaceutical services, June, p. 783.
46. The P&T committee and the industry, July, p. 907.
47. The formulary and antimicrobial restrictions, August, pp. 1029-1031.
48. The need for a drug information service, September, p. 1159.
49. Hospice care: Science follows practice, October, p. 1289.
50. Consumerism and drugs, November, p. 1417.
51. Prescribing by pharmacists, December, p. 1557.

continued

PKY183265996

Editorials- continued

- Lipman AG. Hospital Formulary 1983;18
- 47. A journal with a mission, January, p. 11.
 - 48. Costs of care, February, p. 139.
 - 49. The third annual Hospital Formulary award, March, p. 241.
 - 50. TEFRA and the P&T committee, April, p. 365.
 - 51. Age: A growing P&T concern, May, p. 469.
 - 52. Philosophy and practice of the P&T committee, June, p. 599.
 - 53. Quality drug therapy at affordable costs, July, p. 673.
 - 54. A new formulary statement and formulary service, August, p. 771.
 - 55. Therapeutic substitution, September, p. 841.
 - 56. Formularies and the feds: The alphabet soup expands, October, p. 941.
 - 57. Prescription drug advertising to the consumer, November, p. 1025.
 - 58. Directions and trends, December, p. 1093.
 - 59. Expanding our editorial expertise, December, p. 1114.
- Lipman AG. Hospital Formulary 1984;19
- 60. Looking ahead, January, p. 7.
 - 61. Clinical pharmacy service in a long term care facility, February, p. 105.
 - 62. Our litigious environment, March, p. 246.
 - 63. Drug utilization review revisited, April, p. 277.
 - 64. The danger of ignorant patients, May, p. 349.
 - 65. Three hits, no runs and two left on, June, p. 441.
 - 66. P&T committees in the spotlight, July, p. 519.
 - 67. Cost implications of future new drugs, August, p. 635.
 - 68. Patients' perceptions and self medication, September, p. 749.
 - 69. The cost effectiveness of drug therapy, October, p. 875.
 - 70. The cruel hoax of heroin, November, p. 999.
 - 71. Satisfaction from P&T Committee service. December, p. 1097.
 - 72. Lipman AG. The hue and cry for heroin. Canad J Hosp Pharm 1984;37:131.
 - 73. Lipman AG. Progress and problems with pain. Clin Pharm 1985;4:80-81.
- Lipman AG. Hospital Formulary 1985;20
- 74. Drug samples in the hospital, January, p. 15.
 - 75. Trends in pharmacy services, February, p. 159.
 - 76. The JCAH and the P&T committee, March, p. 263.
 - 77. What do consumers think about prescription drugs? April, p. 413.
 - 78. Sharing in a newly competitive industry, May, p. 563.
 - 79. Communicating, June, p. 685.
 - 80. Extemporaneous formulations: A continuing need, July, p. 787.
 - 81. Medication compliance, August, p. 876.
 - 82. Advances in pain management, September, p. 951.
 - 83. Nonprescription drug counseling, October, p. 1035.
 - 84. Our changing health care system: Strategies for responding, November, p. 1175.
 - 85. The FDA's plan to action, December, p. 1211.
- Lipman AG. Hospital Formulary 1986;21
- 86. Direct-to-consumer prescription drug advertising, January, p. 4.
 - 87. The P&T committee and prescribing patterns, March, p. 261.
 - 88. Hospital pharmaceutical services national survey results, April, p. 417.
 - 89. Downsizing while maintaining quality care, May, p. 543.
 - 90. Formulary systems in HMOs, June, p. 637.
 - 91. The pharmacist's role in infection control, July, p. 749.
 - 92. The explosion of generic pharmaceuticals, August, p. 827.
 - 93. New drug delivery systems in the immediate future, September, p. 901.
 - 94. The future is fast upon us, October, p. 987.
 - 96. Changes in pharmacists' functions: Implications for P&T committees, December, p. 1175.

-continued-

Editorials (continued)

- Lipman AG. Hospital Formulary 1987;22
- 97. Pain therapy: Time for a change, January, p. 13.
 - 98. Drug samples in the hospital revisited, February, p. 123.
 - 99. Biotechnology and the P&T committee, March, p. 221.
 - 100. Managing the P&T committee agenda, April, p. 331.
 - 101. The new drug diversion bill, May, p. 417.
 - 102. State of the pharmaceutical industry, June, p. 509.
 - 103. Physician dispensing: P&T committee implications, July, pp. 607, 610 (Weintraub M, Lipman AG).
 - 104. Dealing with "me-too" drugs, August, p. 693.
 - 105. The boom in home-use in-vitro diagnostics, September, p. 759.
 - 106. Prescription drug poisonings and the P&T committee, October, p. 817
 - 107. Pharmacist-conducted drug regimen review, November, p. 999.
 - 108. A year end review of P&T committee accomplishments, December, p. 999.
- Lipman AG. Hospital Formulary 1988;23
- 109. The paradox of therapeutic progress, January, p. 13.
 - 110. The courage of our convictions, February, p. 117.
 - 111. The FDA drug review process, March, p. 211.
 - 112. JCAH to JCAHO: More than a change in name, April, p. 313.
 - 113. Discharge medications and continuity of care, May, p. 410.
 - 114. The impact of drug usage evaluations, June, p. 499.
 - 115. Physicians' drug knowledge, July, p. 567 (Lipman AG, Weintraub, M).
 - 116. Medication use by older Americans, August, p. 625.
 - 117. The state of the pharmaceutical industry, September, p. 682.
 - 118. The need for soft science, October, p. 769.
 - 119. The case against multidisciplinary health care, November, p. 859.
 - 120. Pharmacy dynamics, December, p. 948.
- Lipman AG. J Pharm Care Pain Symptom Control. 1993;1.
- 121. Pharmaceutical care and symptom control, number 1, pp. 1-3.
 - 122. Clinical guidelines for symptom control, number 2, pp. 1-4.
 - 123. Perceptions of cancer pain and its treatment, number 3, pp. 1-4.
 - 124. The stepped approach to cancer pain management, Number 4, pp. 1-3.
- Lipman AG. J Pharm Care Pain Symptom Control. 1994;2.
- 125. The federal cancer pain guideline, Number 1, pp. 1-4.
 - 126. The growth of interdisciplinary pain management is a double edged sword, Number 3, pp. 1-6
 - 127. Practice policies in pain and symptom control, Number 4, pp. 1-4.
- Lipman AG. J Pharm Care Pain Symptom Control. 1995;3.
- 128. The editorial board. Number 1:1-4.
 - 129. Are pharmacists barriers to cancer pain management? Number 2:1-4
- Lipman, AG. J Pharm Care Pain Symptom Control. 1996;4
- 130. A tribute to Robert Angarola. Number 3:1-2
131. Compounded Medications Can Compound Medication Problems. Number 4:1-3
- Lipman, AG. J Pharm Care Pain Symptom Control. 1997;5
- 132. Must we make the courts our last resort? Number 1:1-3
 - 133. The reinventing of the agency for health care policy and research ahcpr. Number 2:1-4.
 - 134. Opioids in chronic nonmalignant pain: the debate continues. Number 3: 1-2.
 - 135. Symptom control: more than the management of pain. Number 4: 1-2.
- Lipman, AG. J Pharm Care Pain Symptom Control. 1998;6
- 136. Managing the Information Explosion. Number 1:1-4
 - 137. The Dilemma of Alternative Medicine. Number 2:1-4
 - 138. Constipation Hurts. Number 3:1-3
- Lipman, AG. J Pharm Care Pain Symptom Control. 1999;7
- 139. Science and anecdote: synergistic or antagonistic Number 1:1-1-2
 - 140. A call for more evidence-based pharmacotherapy. Number 2:7-10.
 - 141. Patient empowerment. Number 3:1-4.

PKY183265998

142. Silent complicity in assisted death. Number 3:5-6

-continued-

Editorials- continued

143. Lipman, AG. J Pharm Care Pain Symptom Control. 2000;8
Pain Standards Number 2:
144. NIH Consensus Statements, Number 2:
144. Drug-Diet Interactions in Palliative Care, Number 3:
Lipman AG. J Pharm Care Pain Symptom Control. 2001;9
145. Defining hospice and palliative care. (1):1-3.
146. Are pain clinicians generalists or specialists? (2):1-2
147. Expanding palliative care in society. (2):5-6.

Drug Therapy Reviews

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1975;43
1. Salicylate-induced drug interactions, Jan. 15, p. 169.
 2. Oral anticoagulant drug interactions I, Feb. 1, p. 139.
 3. Oral anticoagulant drug interactions II, Feb. 15, p. 191. Addendum, April 15, p. 54.
 4. Oral anticoagulant drug interactions III, March 1, p. 127.
 5. Oral anticoagulant drug interactions IV, March 15, p. 199.
 6. Oral anticoagulant drug interactions V, April 1, p. 103.
 7. Drug interactions involving antiepileptic agents I, April 15, p. 151.
 8. Drug interactions involving antiepileptic agents II, May 1, p. 61.
 9. Antidiabetic drug interactions I, May 15, p. 103.
 10. Antidiabetic drug interactions II, June 1, p. 71.
 11. Effects of antidiabetic agents on clinical laboratory test results, June 15, p. 105.
 12. Drug interactions involving diuretics, July 1, p. 119.
 13. Drug interactions with digitalis glycosides, Aug. 1, pp. 111-112.
 14. Drug interactions involving antidepressant agents I, Sept. 1, pp. 79-80.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1975;43
15. Drug interactions involving antidepressant agents II, Sept. 15, pp. 81-82.
 16. Drug interactions involving antidepressant agents III, Oct. 1, p. 69.
 17. Interactions of skeletal muscle relaxants used in surgery, Oct. 15, pp. 73-74.
 18. Drug interactions involving antiarthritic agents, Nov. 15, pp. 79-80.
 19. Drugs for an emergency kit, Dec. 1, pp. 87-88.

Continued

PKY183265999

Drug Therapy Reviews - continued

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1976;44
20. Drugs that may precipitate hemolytic anemia in patients deficient in G-6-PD, Jan. 1, pp. 91-92.
 21. Drug-induced ototoxicity, Jan. 15, pp. 109-110.
 22. Drugs interfering with urinary glucose tests, Feb. 1, pp. 105-106.
 23. Drug interactions with alcohol, Feb. 15, pp. 67-69.
 24. Drug and chemical induced photosensitivity I, March 1, pp. 81-82.
 25. Drug and chemical induced photosensitivity II, March 15, pp. 97-98.
 26. Fiber-free semisynthetic liquid diets, April 1, pp. 99-100.
 27. Drug-induced coloration of the urine, April 15, pp. 83-84.
 28. Drug-induced coloration of the feces, May 1, p. 79.
 29. Drug-induced eosinophilia, May 15, pp. 95-96.
 30. Drug-induced hepatotoxicity I, June 1, pp. 105-106.
 31. Drug-induced hepatotoxicity II, July 1, p. 85.
 32. Hyperuricemia and serum uric acid test changes induced by drugs, Aug. 1, pp. 101-102.
 33. Equivalence of oral theophylline dosage forms, Sept. 1, pp. 79-80.
 34. New nonsteroidal anti-inflammatory agents, Sept. 15, pp. 25-26.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1976;44
35. Drug-induced hypokalemia, Oct. 1, pp. 97-98.
 36. Drug-induced gynecomastia, Oct. 15, pp. 69-70.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1976;44
37. Drug unitage, Nov. 1, pp. 93-94.
 38. Drug-induced thrombocytopenia, Nov. 15, pp. 75-76.
 39. Drug-induced fever, Dec. 1, pp. 87-88.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1977;45
40. Drug-induced ocular toxicity I, Jan. 1, pp. 87-88.
 41. Drug-induced glaucoma, Jan. 15, pp. 103-104.
 42. Drug-induced ocular toxicity II, Feb. 1, pp. 81-82.
 43. Drug-induced optic neuritis, Feb. 15, pp. 55-56.
 44. Immunization and prophylaxis for foreign travel, March 1, p. 67.
 45. Antimicrobial agents in breast milk, March 15, pp. 89-90.
 46. Biological half-lives in antimicrobial agents, April 15, pp. 57-58.
 47. Drugs associated with impotence, May 15, pp. 81-82.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1977;45
48. Sodium content of commonly used parenteral antibiotics, May 30, pp. 83-84.
 49. Sodium content of frequently used analgesics and gastrointestinal drugs, June 15, pp. 59-60.
 50. Alcohol content of commonly used drugs, June 15, pp. 43-44.
 51. Diabetic sugar urine tests, July 15, p. 109.
 52. Temperature requirements for drug storage, August 15, p. 103.
 53. Vitamins: Availability and uses, Sept. 15, pp. 63-64.
 54. Drug-induced elevations of serum potassium levels, Sept. 30, pp. 59-60.
 55. Prescription drugs containing aspirin, Oct. 15, p. 115.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1977;45
56. Drugs that can elevate creatine phosphokinase, Oct. 30, pp. 55-56.
 57. Nonprescription drugs containing aspirin, Nov. 15, pp. 79-80.
 58. Drug interferences with thyroid function tests, Dec. 15, pp. 97-98.
- Lipman AG. Supplemental Vitamin Therapy. Physician Assistant. 1977;2:23.
- Lipman AG. Non-steroidal anti-inflammatory agents. Physician Assistant. 1977;2:32.
- Lipman AG. Amikacin: A new aminoglycoside antibiotic. Physician Assistant. 1977;2:28.

Continued

PKY183266000

Drug Therapy Reviews - continued

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1978;46
62. Dosage schedules for antihypertensive drugs, Jan. 15, pp. 69-70.
 63. Potential interactions between monoamine oxidase inhibiting drugs and food, Jan. 30, p. 76-7.
 64. Potential interactions between monoamine oxidase inhibitors and nonprescription drugs, Feb. 28, pp. 45-46.
 65. Insulin guidelines: Mixing, onset, peak and duration, Mar. 15, pp. 123-124.
 66. Comparing the benzodiazepines, Mar. 30, pp. 171-172.
 67. Suggested monitoring parameters for total parenteral nutrition, Apr. 15, pp. 125-126.
 68. Drug dosage considerations in elderly patients, Apr. 30, pp. 87-88.
 69. Effects of maternal drug use near term, May 15, pp. 113-114.
 70. Drugs that may cause proteinuria, May 30, p. 155.
 71. Malaria prophylaxis for travelers, June 15, pp. 169-170.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1978;46
72. Drugs that interfere with sulfobromophthalein tests, June 30, p. 77.
 73. Drugs excreted in breast milk, July 15, pp. 155-156.
 74. Drug interferences with urine glucose tests, Aug. 15, pp. 195-196.
 75. Drug interactions involving propranolol, Sept. 15, pp. 83-84.
 76. Drug interactions with oral contraceptives, Sept. 30, p. 117.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1978;46
77. Drug interactions involving digitalis, Oct. 15, pp. 199-200.
 78. What to do about your patient's iron needs, Oct. 30, pp. 69-70.
 79. Analgesics in breast milk, Nov. 15, pp. 101-102.
 80. Tetracycline drug interactions, Nov. 30, pp. 149-150.
 81. Drugs which may induce diabetes, Dec. 15, p. 153.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1979;47
82. Cigarette smoking and drugs, Jan. 15-Jan. 30, pp. 103-104.
 83. Drug excretion affected by urinary pH, Jan. 30-Feb. 15, p. 139.
 84. Drug interactions with aspirin, Feb. 15-Feb. 28, pp. 187-188.
 85. Comparison of theophylline dosage forms, Feb. 28-Mar. 15, pp. 65-66.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1979;47
86. Pharmacologic effects of marijuana, Mar. 15-Mar. 30, pp. 105-106.
 87. Drugs affect absorption and excretion of nutrients, Mar. 30-Apr. 15, p. 149.
 88. Narcotic analgesic comparisons, Apr. 15-Apr. 30, pp. 195-196.
 89. Aspirin's role in preventing emboli, Apr. 30-May 15, p. 77.
 90. Smoking's effect on health, May 15-May 30, pp. 91-92.
 91. Drug-induced hyperkalemia, May 30-June 15, pp. 153-154.
 92. Drug interactions with cardiac antiarrhythmics, June 15-June 30, pp. 173-174.
 93. New drugs of 1978, June 30-July 15, pp. 75-76.
 94. Drug-induced eosinophilia, July 15-Aug. 15, pp. 179-180.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1979;47
95. Adverse reactions to cimetidine, Aug. 15-Sept. 15, pp. 163-164.
 96. Vitamin toxicity, Sept. 15-Sept. 30, pp. 88-89.
 97. Drug-induced serum cholesterol elevations, Sept. 30-Oct. 15, pp. 119-120.
 98. Oral anticoagulant interactions with analgesics and anti-inflammatories, Oct. 15-30, pp. 185-6.
 99. New drugs which may be available soon, Oct. 30-Nov. 15, pp. 73-74.
 100. Oral anticoagulant interactions with anti-infective drugs, Nov. 15-Nov. 30, pp. 73-74.
 101. New recommendations for the treatment of gonorrhoea, Nov. 30-Dec. 18, pp. 133-134.
 102. Oral anticoagulant interactions with hormonal drugs, Dec. 15, 1979-Jan. 15, 1980, pp. 141-142.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1980;48
103. Drug interferences with urinary pregnancy tests, Jan. 15-Jan. 30, pp. 103-104.
 104. Sodium content of some commonly used antacids, Jan. 30-Feb. 15, pp. 123-124.
 105. Drug-induced direct positive Coombs' tests, Feb. 15-Feb. 29, pp. 157-158.
 106. Prescription analgesics: How much aspirin do they contain, Feb. 29-Mar. 15, pp. 75-76.
 107. Which drugs may induce eosinophilia? Mar. 15-Mar. 30, pp. 77-78.
 108. Interactions between monoamine oxidase inhibitors and food, Mar. 30-Apr. 15, pp. 133-134.

-continued-

PKY183266001

Drug Therapy Reviews (continued)

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1980;48
109. Drug-induced angina pectoris, Apr. 15-Apr. 30, pp. 113-114.
110. Nutritional deficiencies and alcohol abuse, Apr. 30-May 15, pp. 77-78.
111. Drug interference with neuromuscular transmission, May 15-May 30, pp. 71-72.
112. Drug-alcohol interaction, May 30-June 15, pp. 125-130.
113. Effect of drugs in breast milk, June 30-July 15, pp. 71-72.
114. Drug-induced elevation of SGOT and SGPT, II, July 15-Aug. 15, pp. 161-162.
115. A checklist of new drugs, Sept. 15-Sept. 30, pp. 71-72.
116. Marijuana as an antiemetic, Sept. 30-Oct. 15, pp. 121-122.
117. Changes in official drug names, Oct. 15-Oct. 30, pp. 109-110.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1980;48
118. OTC treatment for hemorrhoids, Oct. 30-Nov. 15, p. 77.
119. Alcohol free cough preparations, Nov. 15-Nov. 30, pp. 81-82.
120. Use of the new rabies vaccine, Nov. 30-Dec. 15, pp. 139-140.
121. Drug-induced deafness, Dec. 15, 1980-Jan. 15, 1981, pp. 147-148.
122. Lipman AG. Wirkungen von Arzneimittel in der Muttermilch, Extracta Gynecologica (Berlin). 1981;5:239-240.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1981;49
123. Single daily doses of drugs to aid compliance, Jan. 15-Jan. 30, pp. 89-90.
124. Drug interactions with aspirin, Jan. 30-Feb. 15, pp. 107-108.
125. Drug interactions with beta-blockers, Feb. 15-Feb. 28, pp. 161-162.
126. Drug-induced impotence, Feb. 28-Mar. 15, pp. 75-76.
127. Drug-induced elevations of serum cholesterol, Mar. 15-Mar. 30, pp. 75-76.
128. Drug-induced hypokalemia, Mar. 30-Apr. 15, pp. 141-142.
129. Drug-induced fever, April, pp. 137-138.
130. Drug-induced hyperkalemia, May, pp. 213-214.
131. Drug-induced photosensitivity, June, pp. 195-196.
132. Drugs which may cause an Antabuse-type reaction, July, pp. 185-186.
133. Tricyclic antidepressant interactions, August, pp. 151-152.
134. Antacids, September, pp. 203-204.
135. Oral anticoagulants: Caution with concurrent drugs, October, pp. 211-212.
136. Oral contraceptive interactions, November, pp. 227-228.
137. Tailoring prescriptions to avoid toxicity in the elderly, December, pp. 179-180.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1982;50
138. Digitalis glycoside drug interactions, January, pp. 281-282.
139. Drug-induced diabetes, February, pp. 273-274.
140. New drugs of 1980-81, March, pp. 223-224.
141. Drug-induced gynecomastia, April, pp. 179-180.
142. Drug vitamin interactions, May, pp. 257-258.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1982;50
143. Active immunizing agents update, June, pp. 229-230.
144. Passive immunizing agents update, July, pp. 199-200.
145. Drug-alcohol interactions, August, pp. 229-230.
146. Non-steroidal antiinflammatory drugs, September, pp. 227-228.
147. Drug-induced angina pectoris, October, pp. 261-264.
148. Propranolol drug interactions, November, pp. 281-282.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1983;51
149. Cardiovascular effects of psychotropic drugs, Feb., pp. 241-242.
150. New drug checklist, March, pp. 289-290.
151. Effects of smoking on drugs, April, pp. 207-208.
152. Drug-induced photosensitivity, May, pp. 279-280.
153. Comparing the benzodiazepines, July, pp. 216-217.
154. Which drugs cause dependence? August, pp. 205-206.

PKY183266002

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER
 IN COMMONWEALTH OF KENTUCKY, EX REL. JACK CONWAY, ATTORNEY GENERAL v. PURDUE PHARMA L.P., ET AL.,
 CIVIL ACTION NO. 07-CI-OI 303 (PIKE COUNTY CIRCUIT COURT)

P-27120 _ 00025

-continued-

Drug Therapy Reviews (continued)

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1983;51
155. Drug-induced thrombocytopenia, September, pp. 247-248.
156. Which drugs cause extrapyramidal symptoms? October, pp. 243-244.
157. Benzodiazepines and driving ability, November, pp. 221-222.
158. Drug-induced hyperlipidemia, December, pp. 107-108.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1984;52
159. Comparing the nonsteroidal antiinflammatory drugs, Jan., p. 264.
160. Drug interactions with H₂ receptor blockers, Feb., pp. 259-260.
161. New drugs of the past years, March, pp. 251-252.
162. Clinical drug trials in myocardial infarct patients, April, pp. 210-211.
163. Drug use in pregnancy, labeling categories, May, p. 211.
164. FDA classification system for new drugs, June, pp. 237-238.
165. Caffeine content of common beverages and foods, August, p. 145.
166. Drugs that may cause infertility, September, pp. 231-232.
167. Toxicity linked to vitamins B and C overdose, Oct., pp. 271-272.
168. Rx to OTC: The switch is on, November, pp. 277-278.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1985;53
169. Drugs which may interact with acetaminophen, Jan., pp. 237-238.
170. Drug interactions with marijuana, February, p. 258.
171. New drugs introduced in the past year, March, pp. 274-276.
172. Comparing the benzodiazepines, May, pp. 272-275.
173. Chronic drug use may be linked to bone disease, June, p. 215.
174. Drug-induced photosensitivity, July, pp. 139-140.
175. How smoking interferes with drug therapy, August, pp. 141-142.
176. Recommendations on immunizations, September, pp. 222-225.
177. Drug interactions with antihypertensive agents, Oct., pp. 169-170.
178. Mixing alcohol and drugs, November, pp. 165-166.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1986;54
179. New H₂ receptor blockers interact with other agents, March, pp. 229-230.
180. New drug update, April, pp. 127-128.
181. How drugs effect vitamin metabolism, May, p. 163.
182. Drug interactions with beta blockers, June, pp. 199-201.
183. Managing intractable hiccups, July, pp. 189-190.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1986;54
184. Treatment guidelines for gonorrhea, November, pp. 175-180.
185. Drugs which may cause hallucinations, December, pp. 153-155.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1987;55
186. Alcohol-drug interactions, February, pp. 165-166.
187. New drug update: The 1986 introductions, March, pp. 212-215.
188. Drugs affecting oral contraceptive efficacy, May, pp. 189-190.
189. Comparing the benzodiazepines, June, pp. 208-211 (Lipman AG, Pryka RD).
190. Drugs that may damage soft contact lenses, June, p. 205.
191. Comparing the NSAIDS, July, pp. 156-159.
192. Orphan drugs, September, pp. 159-160.
193. Antabuse-type reactions, October, p. 187.
194. Effects of smoking on drug therapy, November, pp. 185-186.
195. Managing pressure sores, December, pp. 157-158.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1988;56
196. Aspirin interactions, January, pp. 203-204.
197. Drug-induced orthostatic hypotension, February, pp. 201-202.
198. New drug update: The 1987 introductions, March, pp. 175-176.
199. Comparing the calcium channel blockers, May, p. 169.

-continued-

Drug Therapy Reviews (continued)

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1988;56
- 200. Comparing oral antidiabetic agents, June, p. 203.
- 201. Chronic vitamin toxicity, July, pp. 145-146 (Lipman AG, Oliver BS).
- 202. Antidepressants as analgesics, September (Nielsen J, Lipman AG).
- 203. Caffeine in oral analgesics, October, pp. 197-198.
- 204. Comparing the H₂ receptor blockers, November, p. 191.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1989;57
- 205. Opioid analgesics, January, pp. 161-162.
- 206. New drug update: The 1988 introductions, March, pp. 203-204.
- 207. Home pregnancy tests, April, p. 175.
- 208. Comparing the newer cardiac antiarrhythmic agents, May, p. 203.
- 209. Comparing the NSAIDs, November, pp. 146-149.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1990;58.
- 210. Comparing the hypercholesterolemic agents, February, 145-146.
- 211. New drug update: the 1989 introductions, March, pp. 129-131.

Book Reviews

- 1. Lipman AG. Perspectives on medicines in society. Edited by AI Wertheimer and PJ Bush, Review. Inquiry 1978;15:300-301.
- 2. Lipman AG. Therapeutics. 3rd Edition, by JG Lewis, Review. PA Journal 1978;8:255.
- 3. Lipman AG. Pills, profits and politics. By Silverman and RP Lee, Review. Inquiry 1979;12:366-367.
- 4. Lipman AG. AHFS Drug Formation 86. Edited by GK McEvoy. Hosp Formul 1986;21:964.
- 5. Lipman AG. USP DI, 6th Edition, United States Pharmacopeial Convention. Hosp Formul 1986;21:964.
- 6. Lipman AG. Journal of Musculoskeletal Pain. J Pharm Care Pain Symptom Control. 1993;1 (3):78-79.
- 7. Lipman AG. Martindale, The Extra Pharmacopeia, Int J Pharm Pract. 1994;2:
- 8. Lipman AG. Current and Emerging Issues in Cancer Pain Management. Am J Hosp Pharm. 1994;51:429-430.

Published Audiotape and Videotape Presentations

1. Lipman AG. Providing quality control of pharmaceutical industry representatives' activities within the institution. *Voices* - 12/60. American Society of Hospital Pharmacists, 1973;3:8. (Audio)
2. Lipman AG. Hospices: what, why and how. American Society of Consultant Pharmacists, 1978. (Audio)
3. Lipman AG. Pharmacists' experience in the hospice program. American Pharmaceutical Association, 1979. (Audio)
4. Lipman AG. Storage of drugs. *Medical Journal*. Columbia Presbyterian Medical Center - Scott Broadcast Services, Inc., 1979. (Audio)
5. Lipman AG. Pharmacological approaches to pain. Albert Einstein Medical Center, Philadelphia, PA, 1980. (Audio)
6. Lipman AG. Discarding old medications. *Medical Journal*. Columbia Presbyterian Medical Center - Scott Broadcast Services, Inc., 1980. (Audio)
7. Lipman AG. Symptom control in advanced cancer. National Hospice Organization, McLean, VA, 1980. (Audio)
8. Lipman AG. Drug therapy for symptom control in terminal disease. American Association for the Advancement of Science, Washington, DC, 1982. (Audio)
9. Lipman AG, Ivey M, Gans J. The pharmacist in the hospital and hospice. *Health Field*, NBC Affiliates, 1984. (Video)
10. Lipman AG. New directions in cancer pain management. Scripps Memorial Hospital Cancer Center, La Jolla, CA, 1984. (Video)
11. Lipman AG. The use of narcotics in modern pain control. *Pharma* 1985;1. (Audio)
12. Lipman AG. Rational analgesia. Cancer Symposium, Scripps Memorial Hospital, La Jolla, CA, 1985. (Audio)
13. Lipman AG. Pain control: pure and simple cancer symposium for nurses. Scripps Memorial Hospital, La Jolla, CA, 1985. (Audio)
14. Lipman AG. Developing an effective formulary system. The Wrightwood Groups Inc. for Hospital Satellite Network, 1987. (Video)
15. Lipman AG. Recent advances in postoperative pain management. Aegis Productions for Norwich Eaton Pharmaceuticals, Inc., 1988. (Video)
16. Lipman AG, McCaffery M. Pain and symptom control. National Hospice Organization, 1988. (Audio)
17. Lipman AG. Development of an effective P & T committee. California Society of Hospital Pharmacists, 1989. (Audio)
18. Dahl N, Lipman AG, Selevan J, Lyon RA. Formulary Issues. Drug Information Association, 1991. (Audio)
19. Lipman AG, Berri JJ. Role of the Hospice Pharmacist. American Pharmaceutical Association, 1992. (Audio)
20. Lipman AG. Managing anxiety and depression in palliative care. Scripps Clinic and Research Foundation, 1993. (Audio)
21. Managing the Symptom complex of pain, anxiety and depression. Scripps Clinic and Research Foundation, 1993. (Audio)
22. Guidelines for cancer pain management, National Hospice Organization, 1993. (Two Audios)
23. The expanding role of the pharmacist in the treatment of the terminal cancer patient, NCM Publishers, 1995. (Audio)
24. Analgesic pharmacology. American Academy of Pain Medicine Review Course in Pain Medicine, 1995. (Audio)
25. Adjunctive analgesic drugs in the elderly. American Society of Consultant Pharmacists, 1995. (Audio)
25. Nonopioid analgesic therapy. American Academy of Pain Medicine Review Course in Pain Medicine, 1996. (Audio)
26. Do opioids have a place in chronic nonmalignant pain management? American Academy of Pain Management, 1998. (Audio)
27. Effective pain management utilizing opioids, Purdue Pharma, 1998. (Audio)
28. Advances in the treatment of arthritis. American Society of Consultant Pharmacists, 1998. (Audio)
29. Palliative care: a growing challenge for pharmacists, California Society of Health-system Pharmacists, 1999. (Audio)
30. Clinical practice guidelines: imperfect science and multiple experts, American Pain Society, 1999 (audio)

Letters

1. Lipman AG. A crack in the door: medical service representatives peer review. *Hospitals, JAHA* 1972;46:8.
2. Lipman AG. Utility of preparations of nitrofurantoin. *New Eng J Med* 1974;290:1436-1437.
3. Lipman AG. Relative potencies of glucocorticosteroids. *Amer J Hosp Pharm* 1974;31:632-633.
4. Lipman AG. The dilemma of clinical pharmacy. *Drug Intell Clin Pharm* 1974;8:612.
5. Lipman AG. Judgmental questions and drug information centers. *Amer J Hosp Pharm* 1976;33:20.
6. Lipman AG. Guidelines for prescribers. *Conn Med* 1976;40:289-290.
7. Lipman AG. Drug PRN guidelines. *Conn Med* 1976;40:350-351.
8. Lipman AG. Heparinized solutions in intermittent infusion sets. *Hosp Formul* 1976;11:279.
9. Lipman AG, Decker EL. Rational theophylline therapy. *Drug Intell Clin Pharm* 1977;11:305-306.
10. Yosselson-Superstine S, Lipman AG. Chlordiazepoxide interaction with levodopa. *Annals Intern Med* 1982;96:259-260.
11. Lipman AG. Comment on pain cocktails. *Drug Intell Clin Pharm* 1982;16:332.
12. Lipman AG, Anderson BD. Bioavailability of morphine from rectal suppositories. *Amer J Hosp Pharm* 1984;41:636-7.
13. Lipman AG. Problems with intravenous fluids at the end of life. *Amer J Hospice Care* 1987;4:13.
14. Lipman AG. Hospital-based immunization: a leadership role for hospital pharmacists. *Am J Hosp Pharm*. 1990;47:522-3.
15. Lipman AG. Efficacy of opioids in cancer pain syndromes. *Pain* 1995;63:135.

GRANTS AND CONTRACTSExtramural Grants and Contracts

- 1972-1973 Connecticut Regional Medical Program
Connecticut Regional Drug Information Service, Grant No. 5-G03-RM00008, total budget \$88,000, Principal Investigator.
- 1972-1973 Lilly Research Laboratories
A study of the incidence and severity of phlebitis secondary to intravenous administration of cephalothin sodium and the effect of buffering the infusion on the incidence and severity of phlebitis. \$3,500, Principal Investigator.
- 1973 Hospice Inc., Drug Therapy in Dying Patients
A study and review of pharmacologic management of terminal disease conducted at St. Christopher's Hospice, London, England, \$4,700, Principal Investigator.
- 1973-1975 Lilly Research Laboratories and McGaw Laboratories
A study of the effect of in-line filtration of intravenous antibiotic infusions on the incidence and severity of phlebitis. \$3,500, Co-Principal Investigator.
- 1974-1976 National Cancer Institute
Continuing Care at Home for Patients with Cancer and Their Families, Contract No. NCI-CN-55053, \$9,900, Consultant.
- 1975-1977 National Institutes of Health, National Institute of Arthritis, Metabolism and Digestive Diseases
National Cooperative Gallstone Study, Participation in a study of the efficacy of chenodeoxycholic acid in the treatment of gallstones in situ. Project Staff. Multicenter Patient Compliance Studies. \$7,500, Principal Investigator.
- 1979 National Center for Health Services Research
Cost Utilization Review of IV Administration Sets, Grant No. 1-R03-HS-03394-01, direct costs \$34,921, Principal Investigator - approved but not funded.
- 1980-1982 Burroughs Wellcome Fund
A Program for Faculty Development in Clinical Pharmacy, direct costs \$175,000, Co-Director.
- 1980 USPHS, Health Resources Administration
Drugs in Pain and Symptom Management in Hospice--A Unique Nursing Opportunity, DHEW, No. HRA 232-79-0087, \$2,500.
- 1980-1981 Utah State Department of Health
Provision of Clinical Pharmacy Services, \$25,750, Principal Investigator.
- 1981-1982 Utah State Department of Health
Provision of Clinical Pharmacy Services, \$19,305, Principal Investigator.
- 1981-1982 Raleigh Hills Foundation
Tissue Distribution and Pharmacokinetics of Emetine, \$31,500, Principal Investigator.
- 1982-1983 Utah State Department of Health
Provision of Clinical Pharmacy Services, \$22,912, Principal Investigator.
- 1983 C.R. Bard, Inc.
Controlled Trial of Patient Controlled Analgesia in Post Operative Pain, \$3,000, Principal Investigator.
- 1983-1984 Utah State Department of Health
Provision of Clinical Pharmacy Services, \$27,000, Principal Investigator.
- 1983-1984 Bard Med Systems: Division of C.R. Bard, Inc.
Clinical Investigation of New Infusion Pumps, \$8,900, Principal Investigator.
- 1984-1985 Utah State Department of Health
Provision of Clinical Pharmacy Services, \$28,500, Principal Investigator.
- 1985-1986 Utah State Department of Health
Provision of Clinical Pharmacy Services, \$29,000, Principal Investigator.
- 1986-1988 National Heart, Lung, Blood Institute, National Institutes of Health
Genetic and Developmental Determination of Hypertension, Grant No. HL 24855-07, \$18,000, Co-Investigator.
- 1986-1987 Utah State Department of Health
Provision of Clinical Pharmacy Service, \$27,000, Principal Investigator.
- 1988-1989 Allergan Pharmaceuticals
Custom Care Surgical Kit Study, \$22,090, Principal Investigator.

-continued-

PKY183266009

Extramural Grants and Contracts (continued)

- 1990-1991 Hoechst-Roussel Pharmaceuticals, Inc.
Development of a data system for advanced cancer pain and its management, \$5,000, Principal investigator.
- 1994 Syntex Laboratories
Development of a continuing education program on pathophysiology and management of pain, \$51,425
Principal investigator.
- 1996-1997 Vista Hospice Care Foundation
Postdoctoral training program in pain and palliative care., \$58,000 per year,
Principal investigator.
- 1997-1099 VistaCare Foundation, Scottsdale Arizona
Support for a Post Doctoral Fellowship in Pain and Palliative Care Pharmacy Research, \$66,000 per year,
Principal Investigator.
- 1998-1999 Alza Corporation
Evaluation of E-TRANS (iontophoretic delivery) fentanyl for the treatment of breakthrough pain in conjunction
with chronic pain, \$22,000 Principle Investigator
- 1998-1999 Durect Corporation
Study of subcutaneous sufentanyl in chronic pain management, \$56,000, Principle Investigator
- 1998-1999 Robert Wood Johnson Foundation
Utah partnership for improving care at the end of life planning grant, \$75,000, Steering Committee member.
- 1999-2000 Purdue Pharma
Physician Perceptions of the Role of Opioids in Chronic Nonmalignant Pain, Principle Investigator, \$ 10,000
- 1999-2001 American Pain Society
Development of clinical practice guidelines for pain management in arthritis, Co-Chair-Co Principle
Investigator, \$25,000
- 2000-2002 Robert Wood Johnson Foundation
Utah partnership for improving care at the end of life implementation grant, \$375,000, Steering Committee
member
- 2001 Pharmacia Corp,
Systematic Review Of Adverse Effects of Perioperative, Principle Investigator, \$10,000
- 2001 Pharmacia Corp.
Costs of adverse reactions to opioids in post surgical patients, Co-Investigator, \$125,000
- 2001 American Pain Society Evidence Based Guidelines Program
Systematic Review of the Effect of Pain and Opioids on Immune Response. Principle Investigator, \$15,000
- 2001-2002 Janssen Pharmaceutica
Outcomes study of controlled release opioids in low back pain , Co-investigator, 55,000.
- 2001-2002 Endo Pharamcertuicals
Dermal Lidocaine for Myofascial Pain, Principle Investigator, \$26,000

Intramural Grants and Contracts

- 1978-1981 University of Utah Research Committee
A process study of clinical pharmacist activity in a university teaching hospital, \$2,035, Principal Investigator.
- 1978-1981 Department of Health, Education and Welfare, Biomedical Research Support Grant
Clinical Pharmacist Activity Outcome Study, Grant No. 507-RR-05738-07, \$5,372, Principal Investigator.
- 1991-1992 University of Utah Research Committee
Software development and implementation of a data system for advanced cancer pain and its management,
\$4,940, Principal Investigator.

PKY183266010

Consultant Appointments

1971-1974 Hospice, Inc. (Comprehensive Terminal Care Program) National Cancer Institute Demonstration Project, New Haven, Connecticut - Drug Therapy and Pharmaceutical Services.

1975 American Society of Hospital Pharmacists, Food and Drug Administration - Class Labeling System Corticosteroid Review Panel.

1976-1977 American Academy of Pediatrics, Committee on Nutrition Subcommittee on Amino Acid Modified Diets.

1977-1994 Hospice of Salt Lake (Terminal Care Program) Drug Therapy in Advanced Disease.

1978-1981 National Center for Health Services Research, Health Services Development Grants Study Section.

1978 American Cancer Society Member, Workshop on Curriculum Development for Pharmacists.

1979-1981 Merck Sharp and Dohme, Training of Health Science Associates in Drug Literature Evaluation.

1979-1985 Roxane Laboratories, Columbus, Ohio.

1980-1887 Salt Lake Veterans Administration Medical Center, Development and Maintenance of Comprehensive Pharmaceutical Services and a Residency in Hospital Pharmacy.

1981-1982 Southeast Texas Hospice, Orange, Texas, Member, Advisory Board.

1981 Lederle Laboratories, American Cyanamid Co., Development of Health Professional Information for Piperacillin.

1982 Joint Commission on Accreditation of Hospitals, Consultant Panel for Hospice Accreditation Standards.

1982 Merck Sharp and Dohme, Pain Faculty.

1983-1986 C.R. Bard, Inc., Drug Delivery Systems Development.

1984 Marion Laboratories, Hospital Pharmacy Consultant Panel.

1985 Federal Interagency Committee on Narcotics and Pain.

1986-1990 Purdue Frederick Company, Pain Advisory Board.

1989-1990 Evans Medical LTD, Horsham, West Sussex, England, Drugs for symptom control in advanced cancer

1990-1991 USPHS Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care, Guidelines Development Panel for the Management of Acute, Post-Operative Pain.

1990 National Cancer Institute, Workshop on Cancer Pain, Consultation t the director of the Institute.

1991-1992 USPHS Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care, Guidelines Development Panel for the Management of Pain Associated with Malignancy.

1992 National Cancer Institute, Special Grant Review Panel.

1992-1992-present ASHP Foundation, Pain Management Traineeship Program Development Committee.

1992-1998 American Cancer Society Advisory Group on Cancer Pain Relief

1993-1995 Syntex Laboratories, Pain Management Advisory Committee

1994 National Institutes of Health, National Institute of Nursing Research, Special Grants Review Committee

1994 Astra Pharmaceutical Products, Inc., Reviewer for Astra Clinical Pharmacy Grant Program

1994 National Institutes of Health, National Cancer Institute, Special Grant Review Committee

1996-1999 National Advisory Board, Vista Hospice Care Foundation.; Chairman

1997 Pain Management Consultant Panel, Abbott Laboratories

1997- Purdue Pharma

2000- Pharmacia Corp

2001- Merck Human Health

EDITORIAL APPOINTMENTS

Editorships

2002-present Editor, Journal of Pain & Palliative Care Pharmacotherapy
1991-2001 Editor, Journal of Pharmaceutical Care in Pain & Symptom Control
1993-1995 Editor, Research Update Department, American Pain Society Bulletin
2002-present Editor, Palliative Care Department, American Pain Society Bulletin
1979-1989 Editor, Hospital Formulary

Editorial Board Appointments

1997-present Editorial Board, Journal of Palliative Medicine
1993 Consulting Editor, Analgesia
1993-1995 Editorial Board, American Pain Society Bulletin
1990 Consulting Editor, Pain Management Update, 47th Annual Meeting of the American Society of Hospital Pharmacists
1989-1993 Editorial Board, The IHS Primary Care Provider
1984-1996 Editorial Board, The American Journal of Hospice Care
1984-1994 Editorial Advisory Board, The Hospice Journal
1978-1980 Consulting Editor, American Journal of Hospital Pharmacy
1978-1979 Editorial Board, Journal of Continuing Education in Hospital and Clinical Pharmacy
1977-1978 Contributing Editor, Physician Assistant
1973-1975 Editorial Staff, Connecticut Pharmacist
1971-1977 Contributing Editor, International Pharmaceutical Abstracts

Reviewer Appointments

Referee for: American Journal of Pharmaceutical Education, American Journal of Hospice and Palliative Care, American Journal of Hospital Pharmacy, American Journal of Health-System Pharmacy, Drug Intelligence and Clinical Pharmacy, Hospital Pharmacy, Clinical Pharmacy, Life Sciences, Journal of Pain

1977-present Reviewer, American Hospital Formulary Service
1973-1976 Reference Panel, American Hospital Formulary Service
1973-1978 Staff Consultant, Hospitals, J.A.H.A.
1976-present Consultant, The Medical Letter on Drugs and Therapeutics
1980-1997 Reviewer, American Pharmaceutical Association Handbook of Nonprescription Drugs

UNIVERSITY, PROFESSIONAL AND PUBLIC SERVICE

Memberships and Offices in Professional Societies - International

Federation Internationale Pharmaceutique
Hospital Pharmacists' Section
Academic Section
International Association for the Study of Pain
Subcommittee on Courses and Curriculum
Subcommittee on Curriculum for Pharmacy Schools, Chairman

Memberships and Offices in Professional Societies - National

American Pharmaceutical Association
Delegate from Rhode Island, Student Section, Annual Meetings, 1965, 1966
Policy Committee on Professional Affairs, 1973-74, 1974-75
Liaison Committee with American Academy of Physician's Assistants, 1974-75
Committee on Developing a Statement on Pharmaceutical Services in Hospice Care, 1981-82

-continued-

Memberships and Offices in Professional Societies - National -continued

- American Society of Health-System (formerly Hospital) Pharmacists
 - Alternate Delegate from Connecticut, House of Delegates, 1971
 - Delegate from Connecticut, House of Delegates, 1972, 1974
 - Commission on Goals, 1975-76
 - Council on Clinical Pharmacy and Therapeutics, 1976-77, 1977-78
 - Advisory Panel on Student Membership, 1977-81
 - Joint Committee with American Association of Colleges of Pharmacy, 1979-80
 - Vice Chairman, 1980-81
 - Council on Administrative Affairs, 1981-82
 - Board of Directors, 1982-85
 - Ad Hoc Commission on Pharmacy Practice and Cost Containment, Panel Member, 1985-86
 - Task Force on SIG Program Assessment, 1985-86
 - Information Network for Students, 1985-present
 - Council on Therapeutics, Chairperson, 1988-89, 1989-90
- American Society of Health-System Pharmacists Research and Education Foundation
 - Advisory Panel on Awards, 1976-77, 1977-78
 - Program Development Panel for Traineeship in Pain Management
- American Pain Society
 - Professional Education Subcommittee on Analgesic Regulatory Issues, 1989-1991
 - APS Bulletin Editorial Board, 1993-1994
 - Analgesic Regulatory Affairs Committee, 1992-1997
 - Membership Committee, 1995-present
 - APS-American Academy of Pain Medicine Ethics Task Force, 1998-present
- American Cancer Society
 - Workshop on Curriculum Development for Pharmacists, 1978
 - National Advisory Committee on Cancer Pain Relief, 1992-1993
 - Patient Services Advisory Group on Cancer Pain Relief, 1993-1997
- American Alliance of Cancer Pain Initiatives
 - Board of Directors, 1997-2001
 - Program Committee 1997-1999
- Drug Information Association
 - Committee on Publications, 1976-78
- American Association of Colleges of Pharmacy
 - Distinguished Educator Award Committee, 1980-81
 - Section of Teachers of Clinical Instruction
 - Chairman, Issues Committee, 1978-79, 1979-80
 - College Liaison Representative, 1979-85
- American Society of Hospice Care
 - National Advisory Board, 1985-87
- National Hospice Organization
 - Delegate from Hospice of Salt Lake to Annual Meeting, 1980-81
 - Nominating Committee, 1980-81
 - Education and Training Committee, 1981-82
 - Evaluation and Selections Committee, chairman, 1993
 - Pharmacist Steering Committee of the Council of Hospice Professionals
- United States Pharmacopeial Convention
 - Delegate from the Yale University School of Medicine, 1975-77
 - Delegate from the University of Utah College of Pharmacy, 1980-85
- Hospital Bureau, Inc.
 - Chairman, National Pharmacy Advisory Committee, 1973-75

Memberships and Offices in Professional Societies - Regional, State and Local

- Connecticut Advisory Committee on Food and Drugs
 - Representing Yale University School of Medicine, 1975-76
 - Representing Connecticut Pharmaceutical Association, 1976-77
- Connecticut Hospital Association
 - Council on Shared Services and Facilities, 1975-76
 - Council on Clinical Practice, 1976-77
 - Committee on Purchasing, 1973-75
- Western (U.S.A.) Pain Society
 - Program Committee, 1994
- Connecticut Pharmaceutical Association
 - Executive Committee, 1975-77
 - Joint Committee with Extended Care Facilities, 1971-72
 - Public Relations Committee, 1971-72
 - Subcommittee for Definition of Outpatients, 1971-72
 - Subcommittee for Pharmacy Services to Health Maintenance Organization, 1971-72
 - Joint Conference Committee with the Connecticut Medical Society, 1972-3, 1973-4, 1974-5, Chairman, 1975-76, 1976-7
 - Liaison Committee with the Commission and the School of Pharmacy, 1972-73, 1973-74, 1974-75, Chairman, 1975-76
 - By-Laws Revision Committee, Chairman, 1973-74, 1974-75
- Connecticut Society of Hospital Pharmacists
 - Chairman, Group Purchasing Committee, 1970-71, 1971-72
 - Secretary, Hospital-Community Pharmacists Joint Committee, 1970-71
 - Chairman, Intra-Professional Relations Committee, 1971, 1972, 1973
 - Nominating Committee, 1971
 - Steering Committee, 1972
 - President-Elect and Program Chairman, 1973
 - President and Chairman of the Board of Directors, 1974
 - Legislative Committee 1975, 1976
 - Chairman, PSRO Liaison Committee, 1975-77
 - Chairman, Committee on Standards of Practice, 1975-77
- Utah Pharmaceutical Association
 - Board of Directors, 1978
 - Trustee, 1978-81
 - Interprofessional Relations Committee, Chairman, 1978-79
 - Committee on Professional Affairs, Chairman, 1979
- Utah Society of Hospital Pharmacists
 - Goals and Planning Committee, 1981, 1984
 - Chairman, 1981
 - Student Chapter Advisor, 1985-1992
- Utah Association of Health Professions
 - Delegate, 1979-80
 - Program Committee, 1979-80
- Salt Lake Regional Pharmaceutical Association
 - Board of Directors, 1977-78
 - Program Committee, 1977-78
- Utah Cancer Pain Initiative Cancer Pain Relief-Utah
 - Steering Committee, 1991-present
 - Co-Chairman, 1991-1993
 - Vice President, 1993-1994
 - President, 1995
 - Chair, Role Model Program Planning Committee, 1996

-continued-

Memberships and Offices in Professional Societies - Regional, State and Local (continued)

Utah Division, American Cancer Society
Board of Directors, 1981-1999
Executive Committee, 1986-88
Professional Education Committee, 1980-present
Vice Chairman, 1984-86, Chairman, 1986-88
Think Tank, 1990-present
Chairman 1991-present

University Committees

1971-1977 Yale University Institutional Review Board-Human Investigation Committee
1981-1982 University of Utah, Honors Program Advisory Committee
1981-1984 University of Utah, University Senate
Executive Committee, 1982-84
1981-1982 University of Utah, Honors Program Advisory Committee
1984 University of Utah, Health Sciences Center Primary Care Committee
1984-1985 University of Utah, Health Sciences Prepaid Health Plan Committee
1984-1985 University of Utah, Committee to Review the Structure and Function of the University Senate
1984-1987 University of Utah Writing Board
Education Committee, 1984-85
Executive Committee, 1985-87
1984-1987 University of Utah, Health Sciences Center Clinical Computing Control Committee
1985-1987 University of Utah, Health Sciences Center Clinical Policy Council
1988-1989 University of Utah, International Studies Program
1996-1999 University of Utah, University Retention, Promotion, and Tenure Standards and Review Committee

School of Medicine Committee

1990-present Utah Physician Assistant Program Didactic Teaching Committee

College of Pharmacy Committees

1972-1973 Clinical Council, University of Connecticut School of Pharmacy
1977-1987 Executive Committee, University of Utah College of Pharmacy
1977-1987 Doctor of Pharmacy Committee, University of Utah College of Pharmacy
Chairman, 1989-present
1977-1978, Curriculum Committee, University of Utah College of Pharmacy
1993-1997 Chairman, 1986-1988
1977-1980 Research Committee, University of Utah College of Pharmacy
1979-1985 ad hoc Committee for Clinical Scientist Training, University of Utah College of Pharmacy
1980-1984 BS-MBA Committee, University of Utah College of Pharmacy
1984-1985 Alumni Relations Committee, University of Utah College of Pharmacy
1984-1986 Continuing Education Committee, University of Utah College of Pharmacy
1989-1992 Scholastic Standards Committee, University of Utah College of Pharmacy
1992-1993 Continuing Education committee
1992-1993 Pharm.D. Task Force
1994-1997 Strategic Planning Committee
1995-1997 Dean's Task Force
1995-1996 Professional Experience Program (PEP) Committee
1998-present Computer Committee
1999-2001 Accreditation Committee
1999-present Pharm.D. Seminar Committee
Chairman, 1999-2001

Hospital Committees

1968-1970	Infection Control Committee, USPHS Hospital, Tuba City, Arizona
1968-1979	Disaster Committee, USPHS Hospital, Tuba City, Arizona
1970-1977	Pharmacy and Therapeutics Committee, Yale-New Haven Hospital
1970-1977	Medical Service Representatives Committee, Yale-New Haven Hospital Secretary, 1970-71
1973-1977	Patient Care Studies Committee, Yale-New Haven Hospital
1977-1997	Pharmacy and Therapeutics Committee, University of Utah Hospitals and Clinics Subcommittee on Outpatient Drug Availability, Chairman, 1985-1990 Subcommittee on Aminoglycoside Monitoring, 1986-87
1998-present	Pharmacy and Therapeutics Committee, University of Utah Hospitals and Clinics

PKY183266016

CONTRIBUTED PAPERS

1. Medicine and Pharmacy Aboard New England Whaling Vessels, I: The Captain, An Apothecary-Surgeon at Sea, American Institute of the History of Pharmacy Annual Meeting, Dallas, TX, April 1966 (with G.E. Osborne).
2. Spectrophotofluorometric Determination of Cholesterol Autoxidation Products, original research, University of Michigan College of Pharmacy, 1968.
3. A Senior Level Course in the Contemporary Practice of Pharmacy, University of Michigan College of Pharmacy, February 1968.
4. Clinical Pharmacy Services to Ambulatory Patients, Area Pharmacy Officers Meeting, USPHS, Albuquerque, NM, May 1970.
5. The Care of the Dying Patient - An Interdisciplinary Approach, 6th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, December 1971 (with G.M. McCart and D.F. Beste).
6. The Patient Health Record: A Major Means for Improving Outpatient Pharmacy Services, 7th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1972 (with J.H. Deffenbaugh, Jr.).
7. The Effect of Buffering on Cephalothin Induced Phlebitis, 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, July 1973.
8. Quality Control of Pharmaceutical Industry Representative Activities Within the Institution, 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, July 1973.
9. Drug Literature Abstract and Index Services, 31st Annual Meeting, American Society of Hospital Pharmacists, Chicago, IL, August 1974 (with B.R. Greenberg).
10. Critical Comparisons of Commonly Available Iodophor Solutions and Scrubs, 31st Annual Meeting of the American Society of Hospital Pharmacists, Chicago, IL, August 1974 (with M.J. Rubino).
11. The Effect of In-Line Filtration on the Incidence and Severity of Cephalothin-Induced Phlebitis, 10th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, December 1975 (with E. Decker and J. Cote).
12. Utilization Review of Normal Serum Albumin, 11th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, December 1976 (with A.M. Vengrofski and R.F. Miller).
A Comparative Study of Prospective Surveillance and Voluntary Reporting in Determining the Incidence of Adverse Drug Reactions, 11th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, December 1976 (with B.S. Bennett).
14. Utilization Review of Nutritionally Complete Oral Liquid Diets, 11th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, December 1976 (with C.D. Ponte).
15. The Development of an Auxiliary Faculty of Practicing Pharmacist Role Models for the Provision of Meaningful Community and Hospital General Practice Externships, 79th Annual Meeting of the American Association of Colleges of Pharmacy, Orlando, FL, July 1978 (with J.D. McMahon).
16. An Integrated, Competency Based, Clinical Curriculum for Doctor of Pharmacy Students, 79th Annual Meeting of the American Association of Colleges of Pharmacy, Orlando, FL, July 1978 (with D.K. Devenport).
17. Planning for Decentralization of Pharmacy Services, 13th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, San Antonio, TX, December 1978 (with J.N. Bair and J. Russo, Jr.).
18. Medicine and Pharmacy Aboard New England Whaling Vessels, II: Drugs Used, Their Indications, Applications, Sources and Costs, American Institute of the History of Pharmacy Annual Meeting, Anaheim, CA, April 1979.
19. A Multidimensional Study of Clinical Pharmacist Process, American Society of Hospital Pharmacists 37th Annual Meeting, Anaheim, CA, April 1979 (with B. Page and J.K. Devenport).
20. Experience with a Graduate Program in Institutionalized Pharmacy Management Leading to an M.S. in Hospital Pharmacy, M.B.A. and Residency, American Association of Colleges of Pharmacy 80th Annual Meeting, Denver, CO, July 1979 (with J.N. Bair).
21. Iontophoresis of Lidocaine for Topical Anesthesia, 14th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1979 (with J. Russo, Jr., B. Page and R. Stephen).
22. A Postdoctoral Fellowship Program for Faculty Development in Clinical Pharmacy, American Association of Colleges of Pharmacy 81st Annual Meeting, Boston, MA, July 1980 (with H.H. Wolf).
23. Implementation of a Comprehensive Quality Assurance Program for Pharmaceutical Services, American Society of Hospital Pharmacists 15th Annual Midyear Meeting, San Francisco, CA, December 1980 (with J.N. Bair and N.G. Gisclon).

-continued-

PKY183266017

CONTRIBUTED PAPERS (continued)

24. Education and Service Directed Toward Meeting the Needs of the Elderly, American Association of Colleges of Pharmacy 82nd Annual Meeting, Scottsdale, AZ, July 1981 (with M.D. Higbee and J.K. Devenport).
25. Patient Controlled Analgesia, Fourth World Conference on Pain, International Association for the Study of Pain, Seattle, WA, August 1984 (with R. Kleiman and B. Hare).
26. Identification of Criteria Which May Promote Consistent Documentation of Clinical Pharmacy Activities, American Society of Hospital Pharmacists 20th Annual Midyear Clinical Meeting, New Orleans, LA, December 1985 (with T.P. Lennon, G.E. Dukes and L.M. Strand).
27. Pharmacological and psychological considerations in the management of pain due to metastatic prostatic cancer. Ninth Annual Meeting of the Western U.S.A. Pain Society, Santa Fe, NM, May 1988 (with L.A. Czajkowski).
28. Development and implementation of standards of practice for a multiple institution system of hospitals and ambulatory care centers. American Society of Hospital Pharmacists 24th Annual Midyear Clinical Meeting, Atlanta GA, December, 1989 (with RM Church, RN Herrier, EB Smith, RW Boyce, and V Dwight).
29. A system for concurrent data collection and retrospective analysis of advanced cancer pain and its management. Vth World Congress on Pain, Adelaide, Australia, April, 1990 (with RG Twycross, S Johns and CD Cleland).
30. Complications and Failed Pain Control with Chronic Epidural Pain Management: Mechanisms and Alternatives. American Pain Society 15th Annual Scientific meeting, Washington DC, November 1996 (with S DuPen, M Mauthier and D Coombs).
31. Evidence-Based Drug Therapy Symptom Control Guidelines for Palliative Care. First International Conference on Research in Palliative Care. National Institutes of Health and U.S. Cancer Pain Relief Committee, May 1998 (with L.S. Tyler)
32. Development and Implementation of Evidence-Based Medicine in Palliative Care. American Academy of Hospice and Palliative Medicine 11th Annual Assembly, Snowbird UT, June 1999 (with K Jackson).
33. A Successful Statewide Collaboration to Improve Care at the End of Life. American Academy of Hospice and Palliative Medicine 11th Annual Assembly, Snowbird UT, June 1999 (with J Jacobson and S Beck).
Clinical Practice Guidelines: Making Recommendations Using Imperfect Science and Multiple Experts, American Pain Society 18th Annual Scientific Meeting, Fort Lauderdale FL, October 1999. (with C Miaskowski and A Jacox).
35. Opioid Analgesic Use in Chronic Nonmalignant Pain.. American Society of Health-System Pharmacists 34th Annual Midyear Clinical Meeting, Orlando FL, December, 1999 (with K Jackson and C Rubingh).
36. Initial Efficacy Trial of topical Lidocaine Patches in the Management of Chronic Myofascial Pain. American Pain Society Annual Meeting, Atlanta GA, November 2000. (with A Dalpiaz and S Lorden)
37. The Role of the Treatment Outcomes of Pain Survey Monitoring health-Related Quality of Life. American Pain Society Annual Meeting, Atlanta GA, November 2000. (with D Carr, W Roger, M Ashburn, G Oderda and J Schein)
37. Clinical Beliefs about Opioid Indications and Barriers in Chronic Nonmalignant Pain Management, American Pain Society Annual Meeting, Atlanta GA, November 2000. (with P Grahmann and K Jackson)
38. Cost of Opioid Related Adverse Drug Events in Surgical Patients. American Society of Anesthesiologists, 2001 Annual Meeting, October 2001, New Orleans LA. (with G Oderda, M Samore, R Evans, C Chen, M Ashburn, J Burke) October 2001, New Orleans LA.
39. Topical Lidocaine Patch Therapy for Myofascial Pain. American Pain Society Annual Meeting, Baltimore MD (with A Dalpiaz and S Lorden)

INVITED PRESENTATIONS

1. Clinical Pharmacy Services to Ambulatory Patients, Area Pharmacy Officers Meeting USPHS, Albuquerque, NM, May 1970.
2. The Drug Information Service - An Influence for Rational Drug Therapy, 18th Annual Seminar, New England Council of Hospital Pharmacists, Windsor, CT, May 1971.
3. Pharmaceutical Services to Extended Care Facilities, Connecticut Pharmaceutical Association Annual Convention, East Haddam, CT, June 1971.
4. Monitoring and Recording Drug Interactions in the Institution, University of Connecticut Drug Interaction Continuing Education Program, statewide closed circuit television presentation, November 1971.
5. Drug Information and Clinical Communications, 6th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, December 1971.
6. Group Purchasing of Pharmaceuticals, New England Hospital Assembly, Boston, MA, March 1972.
7. Shared Services in Institutional Pharmacy Practice, Western Massachusetts Society of Hospital Pharmacists, Springfield, MA, June 1972.
8. Handling Drug Interactions and Adverse Drug Reports, Institute on General Practice of Hospital Pharmacy, American Society of Hospital Pharmacists, Boston, MA, July 1972.
9. Drug Information Services in a University Teaching Hospital, Institute on Drug Information and Clinical Communications, American Society of Hospital Pharmacists, Washington, DC, October 1972.
10. Drug Information Requests, Institute on Drug Information and Clinical Communications, American Society of Hospital Pharmacists, Washington, DC, October 1972.
11. Medical Service Representation Peer Review: A Method for Meeting the Needs of the Hospital and the Industry, Industrial Relations Day, Annual Assembly, New York State Council of Hospital Pharmacists, Cooperstown, NY, October 1972.
12. Parenteral Hyperalimentation, Annual Assembly, New York State Council of Hospital Pharmacists, Cooperstown, NY, October 1972.
13. The Drug Information Concept, Special Institute on Clinical Drug Information Services, Connecticut Hospital Association-Connecticut Regional Drug Information Service, New Haven, October 1972.
14. Clinical Case Reviews, 7th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1972.
15. The Pharmacist and Clinical Communications, The Mid-Hudson Valley Society of Hospital Pharmacists, Fishkill, NY, January 1973.
16. Drug Information Services in Connecticut: Current Status, Connecticut Regional Drug Information Service Institute, Farmington, CT, February 1973.
17. Interprofessional Communications, Connecticut Pharmaceutical Association Annual Continuing Education Seminar, Farmington, CT, April 1973.
18. Establishing Clinical Pharmacy Services in a Community Hospital, Worcester Area Hospital Pharmacists Meeting, Worcester, MA, May 1973.
19. Pharmacological Management of Gram Negative Sepsis, Association for Practitioners in Infection Control, New England Branch, New Haven, CT, June 1973.
20. The Pharmacist, The Dying Patient and the Family, Academy of General Practice of Pharmacy, 120th Annual Meeting, American Pharmaceutical Association, Boston, MA, July 1973.
21. Drug Information Utilization and Case Studies, 4th Annual Seminar, Rhode Island Society of Hospital Pharmacists, Seekonk, MA, September 1973.
22. Antibiotic Misuse, presented to the medical staff, W. W. Backus Hospital, Norwich, CT, October 1973.
23. Contemporary Antibiotic Therapy, Hospital Pharmacists of Western Massachusetts, Chicopee, MA, October 1973.
24. Professional Expectations, Connecticut Society of Hospital Pharmacists Annual Student Meeting, Storrs, CT, October 1973.
25. Drug Information Services and Clinical Communications, 8th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, New Orleans, LA, December 1973.

-continued-

PKY183266019

INVITED PRESENTATIONS (continued)

26. Clinical Applications of Broad Spectrum Antibiotics, Delaware Valley Society of Hospital Pharmacists, Philadelphia, PA, February 1974.
27. Drug Therapy in the Terminally Ill Patient, New England Council of Hospital Pharmacists, New England Hospital Assembly, Boston, MA, March 1974.
28. Rational Antibiotic Therapy, presented to the medical staff, Veterans Memorial Hospital, Meriden, CT, April 1974.
29. Drug Literature Evaluation, Annual Assembly, New York State Council of Hospital Pharmacists, Grossinger, NY, October 1974.
30. How to Keep Current, Annual Assembly, New York State Council of Hospital Pharmacists, Grossinger, NY, October 1974.
31. Shared Pharmaceutical Services, New England Hospital Assembly, Boston, MA, October 1974.
32. Symptomatic Drug Therapy in Terminally Ill Patients, Oncology Nurse Education Project, Waterbury Hospital Health Center, Waterbury, CT, November 1974.
33. Professional Standards Review Organizations, Affiliated Chapter Officers Meeting, American Society of Hospital Pharmacists, Miami, FL, December 1974.
34. Drug Therapy in Terminally Ill Patients, 9th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Miami, FL, December 1974.
35. Drug Therapy Considerations, New England Assembly, American Academy of Physicians Assistants, New Haven, CT, February 1975.
36. Pain is Manageable, Nursing Home Administrator Group, Oncology Nurse Education Project, Waterbury Hospital Health Center, Waterbury, CT, April 1975.
37. Monitoring Drug Therapy, Connecticut Association of Health Care Facilities, Vernon, CT, July 1975.
38. Drug Utilization Review, New England Hospital Assembly, Boston, MA, September 1975.
39. Management of Poisoning and Drug Overdoses, presented to the medical staff, W.W. Backus Hospital, Norwich, CT, October 1975.
40. Rational Antibiotic Therapy of Gram Negative Infections, Annual Seminar of the Georgia Society of Hospital Pharmacists, Athens, GA, October 1975.
41. Establishing a Medical Service Representative Peer Review Program, University of Illinois College of Pharmacy - Hospital Pharmacy Service, Chicago, IL, October 1975.
42. Management of Pain in Cancer, statewide telelecture network, Oncology Nurse Education Project, Waterbury Hospital Health Center, Waterbury, CT, October 1975.
43. Prescriptive Practices of Physicians' Assistants and Nurse Practitioners, 4th Annual Conference on New Health Practitioners, Atlanta, GA, April 1976.
44. Monitoring Antibiotic Therapy, Health Facility Surveyor Improvement Conference, Region 4, DHEW, Daytona Beach, FL, June 1976.
45. Pharmaceutical Care in Terminal Illness, 11th Annual Seminar, Maryland Society of Hospital Pharmacists, Ocean City, MD, June 1976.
46. The Role of Drugs in Terminal Symptoms, Institute on Death and Dying, Southern Connecticut State College, New Haven, CT, June 1976.
47. Anticipated Effects of PSRO Programs on Hospital Services, 13th Annual Pharmacy Seminar, Central New York Society of Hospital Pharmacists, Syracuse, NY, September 1976.
48. Symptomatic Drug Therapy in Terminal Disease, presented to the medical staff, Stamford Hospital, Stamford, CT, September 1976.
49. Laboratory Parameters for Monitoring Drug Therapy, Seminar on Laboratory and Diagnostic Tests in the Long-Term Care Patient, Connecticut Pharmaceutical Association, Cromwell, CT, October 1976.
50. Reviewing Drugs for the Pharmacy and Therapeutics Committee, Institute on Effective Use of Clinical Drug Literature, American Society of Hospital Pharmacists, San Antonio, TX, October 1976.
51. Current Status and the Future of Drug Information Provision, Institute on Effective Use of Clinical Drug Literature, American Society of Hospital Pharmacists, San Antonio, TX, October 1976.
52. Use of Drugs by Patients, Seminar on Acute Medical Problems for Physician's Assistants, Maine Medical Center, Portland, ME, February 1977.

-continued-

PKY183266020

INVITED PRESENTATIONS (continued)

53. The Drug Information Service and the Pharmacy and Therapeutics Committee, Annual Seminar of the Western Branches of the Canadian Society of Hospital Pharmacists, Banff, Alberta, Canada, March 1977.
54. Managing Pain in Advanced Neoplastic Disease, Annual Midyear Clinical Meeting, New York State Council of Hospital Pharmacists, Tarrytown, NY, March 1977.
55. Drug-Food Interactions, Seminar on Drug Interactions sponsored by the Rutgers University College of Pharmacy, Elizabeth, NJ, April 1977.
56. Drug-Diet Interactions, Annual Continuing Education Seminar, Connecticut State Dental Society - Connecticut Pharmaceutical Association, Berlin, CT, April 1977.
57. Establishing a Drug Information Center, 28th Annual Seminar of the Texas Society of Hospital Pharmacists, San Antonio, TX, April 1977.
58. Drug-Induced Impotence, Oncology Nurse Education Project, Waterbury Hospital and Health Center, Waterbury, CT, May 1977.
59. Rational Antibiotic Therapy, Annual Continuing Medical Education and Board Review Program for Physician's Assistants, New Haven, CT, September 1977.
60. Treatment of Pain, 5th Annual Maine Nurse-Hospital Pharmacist Conference, Portland, ME, October 1977.
61. Drug-Drug and Drug-Food Interactions, Utah Pharmaceutical Committee on Continuing Education Seminar on Drug Interactions, Salt Lake City, UT, November 1977.
62. The Department of Pharmacy and Drug Administration, Hospital Pharmacies Incorporated Seminar, Denver, CO, November 1977.
63. Changing Patterns in Antibiotic Usage, Hospital Pharmacies Incorporated Seminar, Denver, CO, November 1977.
64. Pharmacologic Approach to Chronic Cancer Pain, Cancer Rehabilitation Program Seminar on Pain Control in Cancer, Portland, OR, November 1977.
65. The Role of the Pharmacist in the Doctor-Patient Relationship, Seminar on Clinical Psychopharmacology, Yale University School of Medicine, Department of Psychiatry, New Haven, CT, December 1977.
66. Drug Therapy in Terminal Disease, Utah Society of Hospital Pharmacists, Salt Lake City, UT, May 1978.
67. Drug Therapy of Pain and Nausea in Cancer, Northern California Society of Hospital Pharmacists - American Cancer Society Program on Supportive Care of the Cancer Patient, Emeryville, CA, September 1978.
68. New Approaches in Pain Control for the Cancer Patient, Cancer Teaching Day, New York State Division, American Cancer Society, Syracuse, NY, November 1978.
69. Pharmacists and the Hospice Movement, 9th Annual Meeting, American Society of Consultant Pharmacists, Atlanta, GA, November 1978.
70. Pharmacology in Pain Control, Advances in Oncology, Interwest Regional Medical Education Center and the American Cancer Society, Salt Lake City, UT, February 1979.
71. Drug Therapy in Chronic Pain, Surgical Staff Conference, L.D.S. Hospital, Salt Lake City, UT, March 1979.
72. Chronic Pain Management, Medical and Nursing Staff, Holy Cross Hospital, Salt Lake City, UT, March 1979.
73. Pharmacists and the Hospice Movement, Academy of Pharmacy Practice, Section on Long Term Care, American Pharmaceutical Association 126th Annual Meeting, Anaheim, CA, April 1979.
74. The Role of Drug Therapy in Cancer Pain, Fourth Annual Midwest Oncology Workshop for Nurses and Pharmacists, Indianapolis, IN, April 1979.
75. Drug Therapy in the Terminally Ill Patient, 87th Annual Convention Utah Pharmaceutical Association, St. George, UT, May 1979.
76. Pharmacological Approaches to Symptom Control, Hospice Development Conference, Oregon Comprehensive Cancer Program, Portland, OR, May 1979.
77. Developing a Quality Assurance Program for Pharmacy Services, American Society of Hospital Pharmacists - Canadian Society of Hospital Pharmacists Institute on Practice, Vancouver, BC, Canada, August 1979.
78. Evaluating Pharmacists Performance, American Society of Hospital Pharmacists - Canadian Society of Hospital Pharmacists Institute on Practice, Vancouver, BC, Canada, August 1979.
79. Altered Pharmacokinetics in the Elderly and Drug Prescribing for the Elderly, Symposium on the Pharmacist and the Geriatric Patient, Colorado Pharmaceutical Association and the University of Colorado School of Pharmacy, Colorado Springs, CO, September 1979.

-continued-

PKY183266021

INVITED PRESENTATIONS (continued)

80. Drug Therapy in Chronic Pain, Medical Staff Conference, FHP/Utah, Salt Lake City, UT, September 1979.
81. Planning for Decentralized Pharmacy Services, Fall Seminar, Idaho Society of Hospital Pharmacists, Sun Valley, ID, September 1979.
82. Infection Control - Drug Utilization Review, Seminar on Anaerobic Infections, Nebraska Society of Hospital Pharmacists, Omaha, NE, October 1979.
83. Approach to Chronic Pain, Medical Service Conference, Veterans Administration Medical Center, Salt Lake City, UT, October 1979.
84. Altered Pharmacokinetics in the Elderly and Drug Prescribing in the Elderly, Symposium on the Pharmacist and the Geriatric Patient, University of Washington School of Pharmacy and the Washington State Pharmaceutical Association, Seattle, WA, November 1979.
85. Symptom Control for the Terminally Ill, Community Home Health Agency, Pharmacists and Nurses Meeting, Longview, WA, November 1979.
86. Drug Therapy in Chronic Pain, Physicians Roundtable Meeting, St. John's Hospital, Longview, WA, November 1979.
87. Hospice: The Program and Its Function, Utah Society of Hospital Pharmacists, Salt Lake City, UT, November 1979.
88. Pain Management, Division of Oncology Conference, College of Medicine, University of Utah, Salt Lake City, UT, November 1979.
89. Drug Therapy in Chronic Pain Syndromes, Symposium on Chronic Pain Syndromes in Medical Practice: Expanded Options 1980, Eisenhower Medical Center and the Arthritis Foundation, Palm Springs, CA, March 1980.
90. Management of Severe, Chronic Pain, Medical Staff Quarterly Meeting, St. Benedicts Hospital, Ogden, UT, March 1980.
91. Pain and Symptom Management, National Hospice Organization Regional Seminar, San Antonio, TX, March 1980.
92. Pharmacology of Narcotic Analgesics in Terminal Pain: New Concepts, Tennessee Society of Hospital Pharmacists, Annual Meeting, Nashville, TN, March 1980.
93. Decentralization of Pharmaceutical Services, Missouri and Kansas Societies of Hospital Pharmacists, Annual Meeting, Kansas City, MO, April 1980.
94. Chronic Pain Management, St. Mark's Hospital Medical Grand Rounds, Salt Lake City, UT, April 1980.
95. Short and Long Term Pain Control, Annual Post Graduate Symposium of the University of Connecticut School of Pharmacy, Storrs, CT, April 1980.
96. Pharmacological Approaches to Pain Management, Symposium on Death and Dying in the Acute Care Hospital, Albert Einstein Medical Center, Philadelphia, PA, April 1980.
97. Treatment of Pain, Health Professionals Continuing Education Program on Care of the Terminally Ill, Oregon State University, Corvallis, OR, May 1980.
98. Pain and Pain Management in the Cancer Patient and Technical Pain Management in Advanced Disease, American Cancer Society, Utah Division, Conference on Human Values and Cancer, Salt Lake City, UT, May 1980.
99. Physiology and Management of Pain, Northwest Association of Physical Medicine and Rehabilitation, Newport, OR, May 1980.
100. Pharmaceutical Education and Health Planning (moderator), Section of Teachers of Clinical Instruction, American Association of Colleges of Pharmacy 81st Annual Meeting, Boston, MA, July 1980.
101. Update on Antibiotic Therapy, Intermountain Infectious Disease Symposium, Idaho Falls, ID, August 1980.
102. Justifying and Implementing Clinical Services, National Institute on Becoming an Effective Hospital Pharmacy Director, American Society of Hospital Pharmacists, Denver, CO, August 1980.
103. Management of Pain in the Terminally Ill Patient, First Annual Western Pharmacy Education Fair, California Pharmacist Association, Newport Beach, CA, September 1980.
104. Drug Therapy in Chronic Pain, Annual Meeting of the Kentucky Society of Hospital Pharmacists, Ft. Mitchell, KY, October 1980.
105. Symptom Control in Advanced Cancer, Annual Meeting of the National Hospice Organization, Los Angeles, CA, November 1980.
106. Rational Use of Non-Narcotic Analgesics, Dolowitz Memorial Workshop of Holy Cross Hospital, Salt Lake City, UT, November 1980.
107. Drug Treatment of Anaerobic Infections, Anaerobic Infections Seminar, Idaho Society of Hospital Pharmacists and Area Health Education Consortium of Treasure Valley, Inc., Boise, ID, November 1980.

-continued-

PKY183266022

INVITED PRESENTATIONS (continued)

108. Symptom Control in Advanced Cancer, Hospice of Cache Valley, Logan, UT, January 1981.
109. Drug Therapy in Chronic Pain, Medical Staff Conference, Logan Regional Hospital, Logan, UT, January 1981.
110. Chronic Pain Management, Southeastern Idaho Center for Health Resources, Inc., Pocatello, ID, January 1981.
111. Pharmacological Management of Pain of Terminal Illness, Conference on Palliative Care, University of Minnesota School of Medicine, Department of Family Practice and Community Health and Hospice St. Paul-Bethesda Lutheran Medical Center, St. Paul, MN, February 1981.
112. Pharmacy Services and Drug Therapy to Patients with Advanced Irreversible Disease, Hospital Institute for Education, Training and Research, Inc., Yale University, New Haven, CT, March 1981.
113. Legitimizing Pharmacy Services, Massachusetts Society of Hospital Pharmacists Sixth Annual Spring Seminar, Framingham, MA, April 1981.
114. Management of Chronic Pain, Pain Symposium sponsored by the University of Pennsylvania School of Medicine, The Williamsport Hospital and the Susquehanna Pharmaceutical Profile Center, Williamsport, PA, April 1981.
115. Decentralized Pharmaceutical Services, Annual Meeting of Oklahoma Society of Hospital Pharmacists, Tulsa, OK, May 1981.
116. Symptom Control in Advanced Cancer, Ogden Surgical Society 35th Annual Medical Meeting, Ogden, UT, May 1981.
117. Drug-Nutrient Interactions, Nutrition-Dietetics Subdivision of the American Association on Mental Deficiency, 105th Annual Meeting, Detroit, MI, May 1981.
118. Drug-Induced Sexual Dysfunction, Psycho-Sexual Workshop sponsored by the Oregon Comprehensive Cancer Program, Portland, OR, June 1981.
119. Pain Management in Terminal Illness, St. Vincent's Hospital Medical Lecture Series and The Visiting Nurse Service, Santa Fe, NM, September 1981.
120. Problems and Therapy in Chronic Pain and Uses and Abuses of Marked Analgesics, Continuing Education Program, University of Utah College of Pharmacy, Salt Lake City, UT, September 1981.
121. New Approaches in Pain Control, Virginia Society of Hospital Pharmacists, Central Region, Richmond, VA, September 1981.
122. Expanding the Scope of Pharmacy Practice: The Pharmacist in Drug Use Control, 2nd Annual Western Pharmacy Education Fair, California Pharmacists Association, Palm Springs, CA, October 1981.
123. Symptom Control. Annual Fall Seminar, Oregon Council of Hospices, Portland, OR, October 1981.
124. Drug Therapy in Cancer Pain, Pain Conference, Oregon Comprehensive Cancer Program, Portland, OR, October 1981.
125. Managing Pain in Advanced, Irreversible Disease, Hospice Program, University of Illinois College of Medicine, Champaign, IL, October 1981.
126. Cancer Pain Control, Hospice Seminar, St. Francis Hospital, New Castle, PA, October 1981.
127. Symptom Control in Advanced Cancer, Whittier Hospital Hospice Symposium, City of Industry, CA, October 1981.
128. Decentralizing for Drug Use Control, Connecticut Society of Hospital Pharmacists, Newington, CT, October 1981.
129. Pain and Symptom Control, Lewis & Clark Rural Area Health Education Center Hospice Workshop, Yankton, SD, October 1981 (telelecture).
130. Hospice and the Pharmacist, Oregon Society of Hospital Pharmacists, Portland, OR, October 1981.
131. Chronic Pain Management, Southeastern Idaho Center for Health Resources, Inc., Idaho State University, and Idaho Falls Hospital, Idaho Falls, ID, November 1981.
132. Pharmaceutical Services in Hospice Care, National Hospice Organization Fourth Annual Meeting, St. Louis, MO, November 1981.
133. Pain Control in the Hospice Patient, Hospice Council for Northern Ohio Conference on Pain Management in Patients with Advanced Irreversible Disease, Cleveland, OH, November 1981.
134. Pain and Symptom Management in Terminal Cancer, University of California at San Francisco and Hospice of Marin, San Francisco, CA, November 1981.
135. The Problem of Pain: A Look at Terminal Illness, Boulder County Hospice, Inc., Boulder, CO, December 1981.
136. Decentralization of Pharmaceutical Services: Past, Present, Future, 16th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, New Orleans, LA, December 1981.
137. Drug Therapy for Symptom Control in Terminal Disease, Annual Meeting of the American Association for the Advancement of Science, Washington, DC, January 1982.

-continued-

PKY183266023

INVITED PRESENTATIONS (continued)

138. Current Concepts of Managing Pain in the Terminally Ill Patient, Nevada Pharmaceutical Association, Las Vegas, NV, March 1982.
139. Symptom Control in Advanced Cancer, Minnesota Society of Hospital Pharmacists, Farmington, MN, March 1982.
140. Supportive Services for the Terminally Ill Patient, Institute on Management of Chronic Disease States: Providing Ambulatory Pharmacy Services, American Society of Hospital Pharmacists, Las Vegas, NV, March 1982.
141. Hospice Care, Pan Pacific II Conference, Honolulu, HI, April 1982.
142. Decentralization for Improved Drug Use Control, Mississippi Society of Hospital Pharmacists, Jackson, MS, May 1982.
143. The Pharmacology of Analgesics for Chronic Pain Control, St. Luke's Hospital, Hospice Symposium, Duluth, MN, May 1982.
144. Symptom Control in Terminal Disease, Palliative Care Symposium, St. John Medical Center, Tulsa, OK, May 1982.
145. Management of Pain Caused by Cancer, 5th Annual Spring Seminar, Northwestern Memorial Hospital Department of Pharmacy, Chicago, IL, April 1982.
146. Control of Pain, University of Minnesota College of Pharmacy and Pharmacy Alumni Society, Minneapolis, MN, May 1982.
147. Control of Pain in Cancer Patients, Conference on Oncologic Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, October 1982.
148. Drug Therapy in the Management of Pain of Advanced, Irreversible Disease. The William M. Lees, MD, Memorial Conference on Hospice Care, Loyola University of Chicago Stritch School of Medicine, Chicago, IL, October 1982.
149. Pain Management in the Terminally Ill, American Society of Consultant Pharmacists, 13th Annual Meeting, New York, NY, November 1982.
150. New Directions in Cancer Pain Management, University of Michigan Medical School, Second Annual Clinical Oncology Program, Ann Arbor, MI, November 1982.
151. Pain: Where Do We Go From Here? Ontario Branch, Canadian Society of Hospital Pharmacists, Annual Meeting, Toronto, Ontario, Canada, December 1982.
152. Chronic Pain Management, University of North Dakota Medical School and the United Hospital, Grand Fork, ND, January 1983.
153. Pain Management Update, Greater Sacramento Cancer Council and University of California at Davis School of Medicine, Division of Hematology - Oncology, Sacramento, CA, January 1983.
154. Patient Education and Counseling, Utah Pharmaceutical Association, 2nd Annual Great Western Conference, Salt Lake City, UT, January 1983.
155. Arthritis Pain Management, Thirteenth Annual Pharmacy Seminar, Ferris State College School of Pharmacy, Big Rapids, MI, April 1983.
156. Pain Management Workshop, Community Care Hospice and Delta County Memorial Hospital, Delta, CO, April 1983.
157. Pain Management and Nonsteroidal Antiinflammatory Drugs, El Paso Society of Hospital Pharmacists and El Paso Pharmaceutical Association, El Paso, TX, May 1983.
158. New Advances in Pain Management, New Hampshire Society of Hospital Pharmacists, Merrimack, NH, June 1983.
159. Motivating Faculty, 84th Annual Meeting, American Association of Colleges of Pharmacy, Washington, DC, July 1983.
160. Current Pharmacologic Management of Cancer Pain, East Bay Cancer Program, Oakland, CA, September 1983.
161. Pain and Symptom Control, Hospital of Abilene, Hendrick Medical Center, Humana Hospital, and Taylor-Jones-Haskell County Medical Society, Abilene, TX, October 1983.
162. Pathophysiology and Management of Pain, Great Lakes Cancer Nursing Conference, Michigan Division, American Cancer Society, Lansing, MI, October 1983.
163. Contemporary Management of Chronic Pain, Greater Cleveland Academy of Pharmacy, Cleveland, OH, October 1983.
164. Contemporary Pain Management in Cancer, John Muir Memorial Hospital, Walnut Creek, CA, November 1983.
165. Current Concepts in the Management of the Cancer Patient, Temple University School of Pharmacy and Pennsylvania Society of Hospital Pharmacists, Philadelphia, PA, November 1983.
166. DRGs from the Hospital Pharmacy Viewpoint, Montgomery Securities Health Care Industries Group, Los Angeles, CA, November 1983.

-continued-

PKY183266024

INVITED PRESENTATIONS (continued)

167. New Directions in Chronic Pain Management, Department of Medicine Conference, Wilmington Medical Center, Wilmington, DE, January 1984.
168. Tumor Conference Consultant on Symptom Control in Advanced Cancer, John Muir Hospital, Walnut Creek, CA, February 1984.
169. Pain Management in Cancer, Third Annual Oncology Seminar, Oncology Conferences and the University of California at San Francisco, February 1984.
170. Non-steroidal Antiinflammatory Drugs in Pain Management, Tidewater Area Society of Hospital Pharmacists, Portsmouth, VA, March 1984.
171. Drug Therapy in the Management of Pain in Advanced, Irreversible Disease, Lee Memorial Hospice Conference, Loyola University of Chicago School of Medicine, Oak Brook, IL, March 1984.
172. New Directions in Pain Control, Tidewater Society of Hospital Pharmacists, Norfolk, VA, March 1984.
173. Use of Analgesics in Mild to Moderate Pain, Mexican-American Physicians Association, San Antonio, TX, April 1984.
174. New Directions in Pain Management, Mississippi Society of Hospital Pharmacists, Jackson, MS, April 1984.
175. Cancer Pain Management, Department of Family Practice Residents Conference, Area Grand Rounds, Calgary General Hospital, Holy Cross Hospital, Calgary, Alberta, Canada, April 1984.
176. Drug Therapy in Chronic Pain, Calgary Pharmaceutical Association, Calgary, Alberta, Canada, April 1984.
177. Hospital Pharmacy in the United States, Association des Pharmaciens des Etablissements de Sante' du Quebec, Montreal, Quebec, Canada, April 1984.
178. Pain Management in Cancer, New Mexico Society of Hospital Pharmacists, Albuquerque, NM, April 1984.
179. Formulary System Controversies in the New Environment of DRGs, Centennial Conference, Montifiore Medical Center, New York, NY, May 1984.
180. Narcotic Analgesics in Cancer Pain Management, School of Pharmacy, University of the Pacific, Stockton, CA, May 1984.
181. Pain Control in Advanced Cancer, Hospice Symposium, Queen of the Valley Hospital, Nappa, CA, May 1984.
182. The Role of Pharmacists in Hospice Care, 105th Annual Meeting, Iowa Pharmacists Association, Des Moines, IA, June 1984.
183. Pain Management in Cancer, Annual Meeting, American Physical Therapists Association, Las Vegas, NV, June 1984.
184. Pain Management in the Cancer Patient, West Texas Cancer Conference, Midland, TX, June 1984.
185. DRGs: Their Impact on Clinical Pharmacy, Symposium on DRGs, University of North Carolina Schools of Medicine and Pharmacy, Chapel Hill, NC, August 1984.
186. Pain Management in Terminally Ill Patients, The Lilly Lecture, 37th Annual Meeting, Canadian Society of Hospital Pharmaceutics, Halifax, Nova Scotia, August 1984.
187. Management of Cancer Pain, 4th Annual Conference on Oncologic Pharmacy and Nursing, New York, NY, September 1984.
188. The Hospital Formulary and P&T Committee in the New Fiscal Environment, Annual Meeting, Arizona Society of Hospital Pharmacists, September 1984.
189. Philosophies of Pain Management, 6th Annual Pharmacy Symposium on Cancer Chemotherapy, The University of Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX, October 1984.
190. New Directions in Cancer Pain Management, 9th Annual Cancer Symposium for Nurses, Scripps Memorial Hospital, La Jolla, CA, October 1984.)
191. Drug Therapy for Chronic Pain, Orange County Pharmaceutical Association, Irvine, CA, October 1984.
192. Pain and Symptom Control: Practical Options for Nurses and Pharmacists, Preconference Seminar, Annual Meeting and Symposium, National Hospice Organization, Hartford, CT, November 1984.
193. Pharmacy Management Strategies in the Era of Prospective Reimbursement, Group Health of Puget Sound, Seattle, WA, December 1984.
194. An Overview of Pharmacological Methodologies in Relief of Pain, Conference on Pain Relief in the Last Phase of Life, Hospice Assistance Program, Portland, OR, January 1985.
195. Controlling Cancer Pain, Practical Oncology Seminar, Swedish Hospital Medical Center, Seattle, WA, January 1985.

-continued-

PKY183266025

INVITED PRESENTATIONS (continued)

196. The Structure and Function of the Pharmacy and Therapeutics Committee in 1985, Hoechst Lecture, Professional Practice Conference, Canadian Society of Hospital Pharmacists, Toronto, Ontario, February 1985.
197. New Approaches in Chronic Pain Drug Therapy, Pharmacy Colloquium, Lane County Pharmaceutical Association, Eugene, OR, February 1985.
198. Decentralization of Pharmaceutical Services for Drug Use Control, Pan Pacific III Conference, Hong Kong, February 1985.
199. Pain Management, Brown County Medical Society, Brownwood, TX, March 1985.
200. A Controlled Pain Study of Patient Controlled Analgesia in Severe Postoperative Pain, Department of Pharmacy Practice, University of Florida, Gainesville, FL, April 1985.
201. Pain Management in Cancer Patients, Northern Illinois Society of Hospital Pharmacists, Chicago, IL, April 1985.
202. Trends in Pharmacy Practice, Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Flagstaff, AZ, April 1985.
203. Pain Management in Cancer, Kaiser Foundation Hospital, Haywood, CA, April 1985.
204. Pain Therapy for the Pharmacist, New England Council of Hospital Pharmacists, New England Hospital Assembly, Boston, MA, April 1985.
205. Pain Teleconference, School of Nursing, Loyola University of Chicago, Chicago, IL, May 1985.
206. Analgesia in Mild to Moderate Pain, Ellsworth Air Force Base Hospital, Rapid City, SD, May 1985.
207. Advanced Pain and Symptom Management of the Terminally Ill Patient, Northern California Hospital Association, Berkeley, CA, May 1985.
208. Drug Therapy of Pain, Pfizer Dialogue, Association of Pharmacy Faculties of Canada Annual Meeting, Halifax, Nova Scotia, Canada, May 1985.
209. Cancer Pain Management, City of Hope National Medical Center, Oncology Conference, Anaheim, CA, June 1985.
210. Pharmacological Needs of a Hospice Program, The First Annual American Conference on Hospice Care, Boston, MA, June 1985.
211. The Pharmacist's Role in Death and Dying, California Pharmacists Association, Maui, HI, June 1985.
212. Integration of Clinical and Distributive Pharmacy Services, 85th Annual Meeting, American Association of Colleges of Pharmacy, San Francisco, CA, July 1985.
213. The Future of Health Care in America - Pharmacy Services, Marion Laboratories Health Care Symposium, Kansas City, MO, July 1985.
214. Acute and Chronic Pain Concepts, Meridian Park Hospital Pain Control Workshop, Tualatin, OR, September 1985.
215. Treatment of Cancer Pain, Practical Therapeutics 1985 Symposium, Rocky Mountain Drug Consultation Service, Denver, CO, September 1985.
216. Management of Pain, Iowa Academy of Family Physicians, Des Moines, IA, September 1985.
217. Administration of Pain Medication, Symposium on Pain Management, Sutter Community Hospitals, Sacramento, CA, October 1985.
218. The Hospital Formulary System, Pain Management, Annual Seminar, New Hampshire Society of Hospital Pharmacists, Manchester, NH, October 1985.
219. Rational Analgesia, Ninth Annual Cancer Symposium, Scripps Memorial Hospital Cancer Center, San Diego, CA, October 1985.
220. Pain Control - Pure and Simple, Fifth Annual Cancer Symposium for Nurses, Scripps Memorial Hospital Cancer Center, San Diego, CA, October 1985.
221. Pain Control in Cancer Patients, St. Lukes Hospital, Milwaukee, WI, November 1985.
222. Pain and Symptom Control: Practical Options for Nurses and Pharmacists, Preconference Seminar, National Hospice Organization Annual Meeting, Washington, DC, November 1985.
223. Recent Advances in Pain Management, Utah Pharmaceutical Association Midyear Conference, Salt Lake City, UT, November 1985.
224. Pain Management of the Cancer Patient, Central Michigan Community Hospital, Mt. Pleasant, MI, November 1985.
225. Current Concepts in the Management of Pain, John Muir Memorial Hospital, Walnut Creek, CA, December 1985.
226. Formulary Evaluation as a Means to Cost Containment, 20th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, New Orleans, LA, December 1985.
227. Pharmacological Management of Pain, St. Mark's Hospital Pain Management Program, Salt Lake City, UT, January 1986.

continued

PKY183266026

INVITED PRESENTATIONS (continued)

228. Pain Management in the Geriatric Patient, Dade County Pharmacists Association, N. Miami Beach, FL, February 1986.
229. Drug Therapy for Chronic Pain, Pharmacy Service, Veterans' Administration Medical Center, La Jolla, CA, February 1986.
230. Pharmacological and Therapeutic Considerations in the Clinical Use of Nonsteroidal Anti-Inflammatory Drugs, Wake Area Health Education Center, Wake Medical Center, Raleigh, NC, March 1986.
231. Drug Indication Approval: Implications for the Health Care Provider, Seminar by the Sea, University of Rhode Island College of Pharmacy, Newport, RI, March 1986.
232. Formulary Systems in the New Fiscal Environment, Idaho Society of Hospital Pharmacists, Boise, ID, April 1986.
233. Pain Management in the Geriatric Patient, Tri Services Pharmacy Officers Meeting, Tripler Army Medical Center, Honolulu, HI, April 1986.
234. Pain Management in the Cancer Patient, Hilo Pharmacists Association, Hilo, HI, April 1986.
235. Drug Therapy for Clinical Pain, Seminar '86, Massachusetts Society of Hospital Pharmacists, Framingham, MA, May 1986.
236. Management of Pain, Tri-Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Flagstaff, AZ, May 1986.
237. Pharmacological and Pharmacokinetic Characteristics of Mixed Agonist Analgesics Buprenorphine Seminar, Annual Meeting, American Society of Health Pharmacists, Denver, CO, June 1986.
238. Pain and Symptom Management in Advanced Cancer, Second Annual American Conference in Hospice Care, San Francisco, CA, June 1986.
239. The Pharmacist's Role in Cancer Pain Management, Cancer Symposium, Wilmington Area Health Education Center, Wilmington, NC, September 1986.
240. Pain and Symptom Control in Cancer, Hospice Care Inc., Dallas, TX, September 1986.
241. Cancer Pain Management, Medical Grand Rounds, Baylor University Medical Center, Dallas, TX, September 1986.
242. Differential Management of Acute and Chronic Pain in Post-Operative and Cancer Patients, Surgical Grand Rounds, Baylor University Medical Center, Dallas, TX, September 1986.
243. Present Role and Effectiveness of the Pharmacy and Therapeutics Committee, Annual Meeting, Michigan Society of Hospital Pharmacists, Plymouth, MI, October 1986.
244. Pathophysiology of Pain, Staff Conference, St. Patrick Hospital, Missoula, MT, October 1986.
245. Drug Therapy Considerations in the Renally Compromised Patient, Annual Meeting, American Society of Consultant Pharmacists, New Orleans, LA, October 1986.
246. Drug Substitutions and the Formulary System, Houston-Galveston Area Society of Hospital Pharmacists, Houston, TX, November 1986.
247. Pain and Symptom Control: Practical Options for Pharmacists and Nurses, Preconference Seminar, Annual Meeting of the National Hospice Organization, Denver, CO, November 1986.
248. The Pharmacist's Involvement in Hospice Care, 21st Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1986.
249. Cancer Pain Management, University of Alabama Hospitals, Departments of Nursing and Pharmacy Services, Birmingham, AL, January 1987.
250. The Pharmacy and Therapeutics Committee, Oklahoma City Area Pharmacists and Hospital Administrators, Oklahoma City, OK, January 1987.
251. New Directions in Pain Management, Southeastern Florida Society of Hospital Pharmacists, Pompano Beach, FL, February 1987.
252. Pharmacological Management of Pain, Medical Staff Conference, Imperial Point Medical Center, Fort Lauderdale, FL, February 1987.
253. Management of Cancer Pain, Family Practice Refresher Course, Utah Academy of Family Physicians, Salt Lake City, February 1987.
254. New Directions in Pain Management, County Pharmaceutical Association, Chico, CA, February 1987.
255. Pain and Symptom Management in Advanced Cancer, Hospice Continuing Education Program for Nurses, Stanford University Hospital, Palo Alto, CA, February 1987.
256. New Directions in Pain Management, Michigan Pharmaceutical Association/Michigan Society of Hospital Pharmacists Interim Meeting, Dearborn, MI, March 1987.

-continued-

PKY183266027

INVITED PRESENTATIONS (continued)

257. Cancer Pain Management, Section on Long Term Care, Wisconsin Pharmaceutical Association, Pewaukee, WI, April 1987.
258. The Pharmacist in Pain Management, Annual Spring Program, New Hampshire Pharmaceutical Association, Manchester, NH, May 1987.
259. Post-Operative Pain Management, Medical Grand Rounds, Bannock Regional Medical Center, Pocatello, ID, June 1987.
260. Management of Pain, Medical Staff Educational Program, Utah Valley Medical Center, Provo, UT, June 1987.
261. Pain and Symptom Control in Advanced Cancer, Third Annual American Conference on Hospice Care, Chicago, IL, June 1987.
262. Pain Management, Alabama Society of Hospital Pharmacists, 66th Annual Convention of the Alabama Hospital Association, Birmingham, AL, June 1987.
263. The Role of the Pharmacist in Managing Pain. Baytown Area Pharmacists, Baytown, TX, June 1987.
264. Pain Management in the Cancer Patient, 12th Annual Seminar in Oncology, City of Hope Medical Center, Costa Mesa, CA, June 1987.
265. Scientific and Clinical Advances in the Management of Pain, Keynote Address, Management of Pain Programme, Hospital Pharmacists' Section, Federation Internationale Pharmaceutique, 47th International Congress of Pharmaceutical Sciences, Amsterdam, The Netherlands, September 1987.
266. Nonsteroidal Antiinflammatory Agents as Analgesics, Second Annual Pharmacy Practice Seminar, The University of North Carolina and The North Carolina Pharmaceutical Association, Wilmington Area Health Education Center, Wrightsville Beach, NC, September 1987.
267. The Future of Health Care in America, keynote presentation, University of Rhode Island College of Pharmacy Continuing Education Seminar, Mansfield, MA, September 1987.
268. Postoperative Analgesia, Second Annual Surgical Chief Residents Conference, Berkeley, CA, October 1987.
269. Selection Criteria for Postoperative Opioid Analgesics, Preconference Symposium, Annual Meeting of the American College of Surgeons, San Francisco, CA, October 1987.
270. Cancer Pain Management, Auburn Faith Community Hospital Medical Staff Conference, Auburn, CA, November 1987.
271. Newer Methods of Administering Analgesics, Sacramento Valley Society of Hospital Pharmacists, Sacramento, CA, November 1987.
272. Advances in Pain Management, Sutter Memorial Hospital Medical Staff Conference, Sacramento, CA, November 1987.
273. Drug Therapy in Pain Management, Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Anchorage, AK, February 1988.
274. Changes in Pharmacy Practice - Opportunities or Treats? Keynote Address, Alaska Pharmaceutical Association 22nd Annual Convention, Anchorage, AK, February 1988.
275. Current Concepts in Pain Management, Alaska Pharmaceutical Association 22nd Annual Convention, Anchorage, AK, February 1988.
276. Symptom Management, Hospice Symposium, Kaiser Permanent Medical Care Program, Oakland, CA, March 1988.
277. Pharmacological Management of Pain, 47th Annual Meeting of the Southern Society of Hospital Pharmacists, Orlando, FL, May 1988.
278. Taking Pride in Our Profession: Sharing Experiences Through Presentation of Publications, U.S. Public Health Service, National Pharmacy Officers Meeting, Phoenix, AZ, May 1988.
279. Formulary Review Process in the Current Fiscal Environment, 45th Annual Meeting of the American Society of Hospital Pharmacists, San Francisco, CA, June 1988.
280. Pharmacokinetics of Opioid Analgesics, International Hospice Institute Symposium, Granby, CO, July 1988.
281. Clinical Use of Nonsteroidal Antiinflammatory Analgesics, 12th Annual Snowbird Conference for Physicians Assistants and Nurse Practitioners, Snowbird, UT, August 1988.
282. Appropriate Use of Analgesics in Chronic Pain Management, Alaska Professional Licensing Boards, Anchorage, AK, October 1988.
283. Pain and Symptom Control: Options for Nurses/Pharmacists, National Hospice Organization, Annual Meeting and Symposium, Preconference Seminar, Orlando, FL, November 1988 (with M. McCaffery).
284. The Physician's Role in Hospice Care. Hospice House, Portland, OR, January 1989.

-continued-

INVITED PRESENTATIONS (continued)

285. Patient Controlled Analgesia: Is it Appropriate in Cancer Pain Management? Conference on Barriers and Approaches to Cancer Pain Management, Good Samaritan Hospital and Medical Center Comprehensive Cancer Program, Portland, OR, January 1989.
286. Drug Therapy in Pain Management, Connecticut Society of Hospital Pharmacists, Hartford, CT, February 1989.
287. Drug Literature Evaluation, Department of Family and Internal Medicine Conference, Phoenix Medical Center, U.S. Public Health Service, Phoenix, AZ, March 1989.
288. Cancer Pain Update, Saint Marks Hospital, Salt Lake City, UT, March 1989.
289. Management of Chronic Pain, Medical Staff Conference, Phoenix Indian Medical Center, U.S. Public Health Service, Phoenix, AZ, April 1989.
290. Drug Literature Evaluation, Greater Phoenix Hospitals Pharmacists Journal Club, Phoenix, AZ, April 1989.
291. Newer Approaches in Drug Therapy of Pain, Salford and Trafford Health Authorities, Greater Manchester, England, April 1989.
292. The Changing Review Process for Antimicrobial Agents in American Hospitals, International Workshop on Clinical Pharmacoeconomics of Antibiotic Drug Use, Herzelia, Israel, June 1989.
293. Symptom Management in Patients with Advanced, Irreversible Disease, Saint Catherine Hospital and Jeanne B. Corley Hospice, Garden City, KS, September 1989.
294. Managing Pain, Utah Pharmaceutical Association, American Fork, UT, October 1989.
295. Development of an Effective P & T Committee, Seminar 89, Annual Meeting of the California Society of Hospital Pharmacists, Anaheim, CA, October 1989.
296. New Findings in the Management of Pain, Family Practice Refresher Course, Utah Academy of Family Practice, Snowbird, UT, February 1990.
297. Management of Pain and Other Symptoms in the Hospice Setting, 137th Annual Meeting, American Pharmaceutical Association, Washington DC, March 1990.
298. Opioid Drug Therapy, Symposium on Pain and Cancer in the Pacific Basin, Australian Pain Relief Association and World Health Organization, Sydney, Australia, April 1990.
299. Pain Management in the Oncology Patient, Symposium on The Challenge of Caring for the Oncology Patient, Thomason Hospital, El Paso TX, May 1990.
300. Evolution of Clinical Pharmacy Services, Greater Cincinnati Society of Hospital Pharmacists, Cincinnati OH, May 1990.
301. Pharmaceutical Services in Chronic Pain Management, Department of Pharmacy Services, University of Cincinnati Hospital, May, 1990.
302. The Pharmacist's Role in Rational Therapeutics, Merrell Dow Lecture in Clinical Pharmacy, University of Manchester and Salford and Trafford Pharmaceutical Service, Manchester, England, May 1990.
303. A Data System for Cancer Pain and its Management, Department of Pharmacy, Faculty of Science, University of Manchester, Manchester, England, May 1990.
304. Problem-Based, Student-Centered Clinical Education, Department of Pharmacy clinical staff and post graduate students, Hope Hospital, Salford, England, May 1990.
305. Pain Management in the Cancer Patient, Twelfth Annual Symposium on Cancer Chemotherapy, The University of Texas M.D. Anderson Cancer Center, Houston
306. Newer Findings in the Management of Pain, Seminar on Pain Management, United Samaritans Medical Center, Danville IL, November 1990.
307. Current Approaches to Pain Management in Advanced Cancer, Hospice medical directors and oncology pharmacists meeting, Kaiser Permanente Medical Centers, Oakland CA, February 1991.
308. High Tech, High Touch Pain Control, Regional Hospice Education Workshop, Kaiser Permanente Medical Centers, Oakland CA, February 1991.
309. Hospice Care: An Exciting Professional Opportunity for Pharmacists, 138th Annual Meeting, American Pharmaceutical Association, New Orleans LA, March 1991.
310. Hospice Care: The Pharmacist's Role in Drug Therapy for Terminally Ill Patients, 138th Annual Meeting, American Pharmaceutical Association, New Orleans LA, March 1991.
311. Management of Pain, Combined Federal Pharmacy Seminar, Phoenix AZ, May 1991.
312. Immunization Update, Combined Federal Pharmacy Seminar, Phoenix AZ, May 1991.

-continued-

PKY183266029

INVITED PRESENTATIONS (continued)

313. Drug Therapy Considerations in the Management of Cancer Pain, American Cancer Society, Albany County Unit, Albany NY, June 1991.
314. The Role of the Pharmacy and Therapeutics Committee in Formulary Management, 27th Annual Meeting, Drug Information Association, Washington DC, June 1991.
315. Chronic Pain Management, Portland Area Pharmacy Officers Meeting, USPHS Indian Health Service, Portland OR, September 1991.
316. Management of Chronic, Benign Pain, Practical Therapeutics, A Western Regional Seminar of the Rocky Mountain Drug Consultation Center, Denver CO, October 1991.
317. New Directions in the Management of Pain, Annual Meeting, Owen Healthcare, Houston TX, October 1991.
318. Management of Pain, Fifth Annual Symposium on Drug Therapy in the Elderly, Veterans Administration Medical Center at Martinez and University of California at San Francisco, Concord CA, October 1991.
319. Pain Management in the Cancer Patient, Indiana Society of Hospital Pharmacists Winter Meeting, Indianapolis IN, January 1992.
320. Hospice Care, Florida Pharmacy Association Research and Education Foundation Oncology Update '92, Destin Beach FL, January, 1992.
321. Role of the Hospice Pharmacist, American Pharmaceutical Association, 139th Annual Meeting, San Diego CA, March 1992.
322. The State of the Art in Pain Management, Symposium on Issues and Advances in Pain Management at the California Society of Hospital Pharmacists Focus '92 Meeting, Monterey CA, April 1992.
323. Pathophysiology of Pain Management, 14th Annual Cancer Symposium, Wake Area Unit of the American Cancer Society, Wake Area Health Education Center and University of North Carolina School of Pharmacy, Raleigh NC, May 1992.
324. Opioid Analgesics in Contemporary Pain Management, 103rd Annual Convention, Oregon State Pharmacists Association, Ashland OR, June 1992.
325. Managing Chronic Pain of Non-Malignant Origin, 103rd Annual Convention, Oregon State Pharmacists Association, Ashland OR, June 1992.
326. NSAIDs: Are They All the Same? Annual Continuing Education Conference of the Utah Academy of Physician Assistants and Utah Nurse Practitioner Conference Group, Snowbird UT, August 1992.
327. Differentiating Acute Pain, Chronic Pain of Malignant Origin and Chronic Non-Malignant Pain. Scientific Symposium on Pain Management, Pharmacy World Congress '92, Lyons France, September, 1992.
328. Rational NSAID Therapy. Utah Academy of Physician Assistants and Utah Nurse Practitioner Group Annual Conference, Snowbird UT, September 1992.
329. The State of the Art in Pain Management and current Approaches to Cancer Pain Management, Symposium on Issues and Advances in Pain Management. Southeastern Michigan Society of Hospital Pharmacists and IMS LTD., Dearborn MI October, 1992.
330. Pain Management. 27th Annual Convention, Alaska Pharmaceutical Association, Anchorage AK, February, 1993.
331. Managing Anxiety and Depression in Palliative Care. Dimensions of Caring 1993: Symptom Management in Palliative Care. Scripps Clinic and Research Foundation and San Diego Hospice, San Diego CA, March 1993.
332. Managing the Symptom Complex of Pain, Anxiety and Depression. Dimensions of Caring 1993: Symptom Management in Palliative Care. Scripps Clinic and Research Foundation and San Diego Hospice, San Diego CA, March 1993.
333. Current Concepts of Pain Theory. Effective Pain Management, Medical Staff Course. North Colorado Medical Center, Greeley CO, March 1993.
334. Managing Chronic, Malignant Pain. North Colorado Medical Center, Greeley CO, March 1993.
335. Clinical Practice Guidelines: Implications for Pharmacy. 38th Annual Ohio Pharmaceutical Seminar, Columbus OH, April, 1993.
336. Costs and Benefits of New Technology and Aggressive Interventions in Pain Management Associated with Advanced, Irreversible Disease. Florida Hospices Symposium, Orlando FL, April, 1993.
337. Update on Pain Management. U.S. Public Health Service Pharmacy Continuing Education Seminar, Phoenix AZ, May 1993.
338. Cancer Pain Management. 15th Midyear Conference, American Society of Consultant Pharmacists, Palm Springs CA, May, 1993.

-continued-

PKY183266030

INVITED PRESENTATIONS (continued)

339. Pain Management in the Cancer Patient, Plenary Session, Cancer Care in the 90s, University of Lethbridge and University of Calgary, Lethbridge. Alberta, Canada, May 1993.
340. New Directions in Pain Management. 50th Annual Meeting, American Society of Hospital Pharmacists, Denver CO, June 1993.
341. Management of Cancer Pain: Internal Medicine Grand Rounds. St. Joseph's Hospital and Medical Center, Phoenix AZ, June 1993.
342. New Directions in Pain Management. Washington State Pharmacists Association Annual Convention, Cour d'Alene ID, June 1993.
343. Management of Cancer Pain. The Jewish Hospital of Cincinnati. Cincinnati OH, June 1993.
344. Current Approaches to Cancer Pain Management, symposium on Issues and Answers in the Management of Pain in association with the Arizona Society of Hospital Pharmacists Annual Meeting, Scottsdale AZ, July 1993.
345. The State of the Art in Pain Management, Florida Society of Hospital Pharmacists Annual Meeting, Orlando FL, August 1993.
346. Drug Therapy in Acute Pain Management, Utah Society of Pain Management Nurses, Salt Lake City UT, September 1993.
347. Pain Management in Long Term Care. Arizona Pharmacy Association Section of Consultant Pharmacists, Phoenix AZ, September 1993
348. Guidelines for Acute Pain and Cancer Pain, National Nurse Practitioner Annual Meeting, Baltimore MD, Oct 1993.
349. Converting the Federal Pain Management Guidelines into Practice, American College of Osteopathic Family Physicians Scientific Lecture Program, Boston MA, October 1993.
350. Converting Pain Management Principles into Practice, Annual Meeting of the American Academy of Family Physicians, Orlando FL, October 1993.
351. Guidelines on Cancer Pain Management. Preconference Symposium, National Hospice Organization Annual Symposium, Salt Lake City UT, October 1993.
352. Agency for Health Care Policy and Research: Acute and Cancer Pain Guidelines, American College of Osteopathic Internists Annual Convention and Scientific Sessions, Scottsdale AZ, October 1993.
353. Interdisciplinary Approaches to Cancer Pain Management, National Video Symposium on Cancer Pain Management, sponsored by the University of California at Los Angeles, Seattle WA October 1993.
354. Acute and Chronic Cancer Pain Guidelines. American Society of Consultant Pharmacists Annual Meeting, New Orleans LA, November 1993.
355. Rational Selection Criteria for Opioid Analgesics, New England Council of Hospital Pharmacists Annual Fall Seminar, Portsmouth NH, November 1993.
356. Current Perspectives on Pain Management. American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta GA, December 1993.
357. Pharmacology of Analgesics and Adjuvants. American Academy of Pain Medicine Review Course in Pain Medicine, Orlando FL, February 1994.
358. Clinical Pain Management. Cache Valley Medical Society and Logan Regional Hospital, Logan UT, February 1994.
359. Pain Management in Long Term Care. Symposium on Geriatric Nursing in Long Term Care, S.D. Care Center, Phoenix AZ, Mar 1994.
360. Using the AHCPR Clinical Practice Guidelines in Practice, Scientific Seminar on Pain Management, 31st Annual Convention and Scientific Seminar, Phoenix AZ, Mar 1994.
361. The Agency for Health Care Policy and Research Cancer Pain Management Guideline. Massachusetts Cancer Pain Initiative, Boston MA, Apr 1994.
362. Effective Professional Education for Cancer Pain Management. National meeting of State Cancer Pain Initiatives, Boston MA, Apr 1994.
363. Pharmacological Pain Management and the Guideline Development Process, Symposium on Federal Clinical Practice Guidelines, Western USA Pain Society, Newport Beach CA, Apr 1994.
364. Management of Chronic, Nonmalignant Pain, Institute for Rehabilitation and Research, Texas Medical Center, Houston TX, Apr 1994.
365. Symptom Control in Advanced, Irreversible Disease. Hospice of the Canyon, Malibu CA, Apr 1994.
366. The Federal Clinical Practice Guideline for Cancer Pain Management. Norris Cancer Center, University of Southern California, Los Angeles CA, Apr 1994.

-continued-

PKY183266031

INVITED PRESENTATIONS (continued)

367. The AHCPR Clinical Practice Guidelines for Acute Pain and Cancer Pain Management, American Society of Pain Management Nurses, Chicago IL, Apr 1994.
368. Pain Management Guidelines. American Society of Consultant Pharmacists Annual Meeting, Boca Raton FL, May 1994.
369. Acute and Cancer Pain Management. Southwest Regional Pharmacy Seminar, Indian Health Service, U.S. Public Health Service, Scottsdale AZ, May 1994.
370. Drug Therapy in Pain Management. American Association of Physicians Assistants Annual Meeting, San Antonio TX, May 1994.
371. Pain Management in Elderly Patients, Veterans Affairs Medical Center Symposium on Geriatric Care. Salt Lake City UT, June 1994.
372. Drug Therapy in Cancer Pain. Hospice of El Paso, El Paso TX, Sept 1994
373. Pain Management Issues and the Federal Clinical Practice Guidelines. Professional Continuing Education Program on Acute and Cancer Pain Management, College of Pharmacy, University of Utah, Salt Lake City UT, Sept 1994.
374. Current Approach to Managing Chronic, Nonmalignant Pain. Symposium on Contemporary Viewpoints on Managing Chronic Pain, McNeil Pharmaceutical, San Francisco CA, Oct 1994.
375. Acute Pain Management, Surgical Grand Rounds, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
376. Cancer Pain Management, Oncology-Hematology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
377. Clinical Pain Management. Department of Internal Medicine Conference, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
378. Pain Management Issues. Department of Pharmacy Conference, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
379. Pain Management in Critical Care Patients. Annual Seminar, Rhode Island Society of Hospital Pharmacists, Providence RI, Oct 1994.
380. The AHCPR Clinical Practice Guidelines for Acute and Cancer Pain Management, Pain Management Symposium, Memorial Medical Center, Las Cruces NM, Oct 1994.
379. Pain Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, Ogden UT Oct 1994
380. The Agency for Health Care Policy and Research Chronic and Cancer Pain Guidelines. National Association for Home Care, 13th Annual Meeting, Chicago IL, Oct 1994.
381. The Future of the Consultant Pharmacist's Role in Pain Management. American Society of Consultant Pharmacists 25th Annual Meeting, Boston MA, Nov 1994.
382. Pain Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, Provo UT Oct 1994
383. Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, Salt Lake City UT Oct 1994.
384. Acute, Post Surgical and Cancer Pain Management, Medical Staff Conference, Yavapai Regional Medical Center, Prescott AZ, Nov 1994.
385. AHCPR Acute and Chronic Malignant Pain Management Guidelines, American College of Osteopathic Family Physicians, 99th Annual Convention, San Francisco CA, Nov 1994.
386. How the Practicing Clinician can use the Federal Clinical Practice Guidelines on Acute and Cancer Pain Management, Utah Medical Association, Salt Lake City UT Dec 1994.
387. Converting Pain Management into Practice. Harris County Pharmaceutical Association and Houston-Galveston Area Society of Hospital Pharmacists, Houston TX, Feb 1995.
388. Analgesic Pharmacology and Therapeutics, American Academy of Pain Medicine Review Course in Pain Medicine, Palm Springs CA, Feb 1995
389. Management of Acute and Chronic Pain, University Learning Systems, Las Vegas, NV, Feb 1995.
390. Pain Control- A Multidisciplinary Approach Columbus Hospital, Great Falls MT, Mar 1995.
391. Pain Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, St. George UT, Mar 1995
392. Cancer Pain Management, Intercollegiate Center for Nursing Education, Spokane WA Mar 1995.
393. Management of Acute and Chronic Pain, University Learning Systems, Marco Island FL, Apr 1995.

-continued-

PKY183266032

INVITED PRESENTATIONS (continued)

394. Integrating the AHCPR Guidelines into Practice. Pain Management: An Interdisciplinary Approach, University of Utah College of Nursing and Utah Pain Management Nurses, Salt Lake City UT, May 1995.
395. Acute and Cancer Pain Management Guidelines. Academy of Managed Care Pharmacy Annual Meeting, Toronto, Ontario, Canada, May 1995.
396. Clinical Practice Guidelines for Managing Cancer Pain. Michigan Association of Osteopathic Physicians and Surgeons. Dearborn, MI, May 1995.
397. Differentiating Acute, Chronic Malignant and Chronic Nonmalignant Pain. Utah Society of Hospital Pharmacists Annual Meeting, Park City UT, May 1995.
398. The Importance of Pain and Symptom Control in a Changing Environment. American Society of Consultant Pharmacists Annual Midyear Conference, San Diego CA, May 1995.
399. The Physician Assistant's Role in Pain Management. American Academy of Physician Assistants 23rd Annual Conference, Las Vegas NV, June 1995.
400. Defining New Standards and Implications for Care for the Nurse Practitioner. American Academy of Nurse Practitioners 10th Annual National Conference, Hollywood CA, June 1995.
401. Understanding and Assessing Pain. First Annual Pain Management Seminar, University of Arizona Colleges of Pharmacy and Nursing and the Arizona Society of Hospital Pharmacists, Scottsdale AZ, July 1995.
402. Analgesic Drugs for Neuropathic and Sympathetically Maintained Pain. Pain Management in Elderly People sponsored by Sepulveda Department of Veterans Affairs Medical Center, Gerontological Society of America, and UCLA Multicampus Program of Geriatrics and Gerontology, Culver City CA, August, 1995.
403. Understanding and Improving Pain Management. Tenth Annual Pharmacy Management Conference, Walker Drug Company, Birmingham AL, August, 1995.
404. The Effective Assessment and Management of Chronic Pain, Maricopa County Pharmacy Association, Phoenix AZ, September, 1995.
405. Cancer Pain Management and the AHCPR Guideline. Northland Hospice, Flagstaff AZ, September, 1995
406. Chronic Nonmalignant Pain Syndromes. Illinois College of Clinical Pharmacy, Chicago IL September 1995.
407. The Importance of Pain and Symptom Control in a Changing Environment. 55th Annual Convention and Scientific Sessions, American College of Osteopathic Internists, Fort Lauderdale FL, October 1995.
408. Managing Chronic Malignant and Nonmalignant Pain in the Outpatient Environment. Seminar '95, California Society of Health-system Pharmacists, Palm Springs CA, October, 1995.
409. Nonsteroidal and Adjuvant Drugs in the Elderly. American Society of Consultant Pharmacists Annual Meeting. San Francisco CA, November 1995.
410. Dose Titration, Polypharmacy and the Role of the Pharmacist in Cancer Pain Management. Pain Resource Network Course, City of Hope Medical Center and Southern California Cancer Pain Initiative, Duarte CA, November 1995.
411. Adjuvant Pharmacotherapy in Cancer Pain. Pain Resource Network Course, City of Hope National Medical Center and the Southern California Cancer Pain Initiative, Duarte CA, November 1995.
412. Chronic Pain Management. El Paso Pharmaceutical Association, El Paso TX, December 1995.
413. Case Studies in Pharmacotherapeutics. Utah Academy of Physician Assistants Recertification Review Course. Park City UT, January, 1996.
414. Cancer Symptom Control. Tumor Conference. St. Thomas Hospital, Nashville TN, February 1996.
415. Pain Management in Cancer and AIDS. Alive Hospice, Nashville TN, February 1996.
416. Pharmacology of Analgesics. American Academy of Pain Medicine Review Course, Orlando FL, February 1996.
417. Management of Cancer and AIDS Pain. Alive Hospice, Nashville TN, February 1996.
418. Cost of Pain to Society and the AHCPR Clinical Practice Guidelines on Pain Management, in Managing Chronic Nonmalignant Pain in Primary Care, University of Utah Health Sciences Center, Salt Lake City UT March 1995.
419. Pharmacist-Patient: Self Care and OTC Analgesics. American Pharmaceutical Association Annual Meeting, Nashville TN, March 1996.
420. Differentiating and Managing Acute, Chronic Malignant and Chronic Nonmalignant Pain. Montana Society of Hospital Pharmacists and University of Montana School of Pharmacy and Allied Health Sciences, Bozeman MT, March 1996.
421. Pain Control with Oral Agents. Society of Surgical Oncology 49th Annual Cancer Symposium, Atlanta GA March 1996.
422. Differentiating and Managing Chronic Pain. Memorial Hospitals Association, Modesto CA, April 1996.

-continued-

INVITED PRESENTATIONS (continued)

423. The AHCPR Guideline: Cancer Pain. HealthInsight, Logan UT, May 1996.
424. Pain Management and Relief. Washington State Hospice Organization. Mt Vernon WA, May 1996.
425. New Approaches to Non-invasive Delivery of Symptom Management. Academy of Hospice Physicians 8th Annual Assembly, Snowbird UT, June 1996.
426. How Chronic Pain Affects the Patient. John C. Lincoln Hospital Pain Management Symposium, Carefree AZ, June 1996
427. Managing Chronic Pain. Mississippi Society of Health-System Pharmacists, Summer Seminar, Biloxi MS, July 1996.
428. Pain Management in the Home. Home Care '96, American Society of Health-System Pharmacists Annual Home Care Meeting, Orlando FL, July 1996.
429. Stumbling Blocks to Effective Pain Management. Visiting Nurse Services of the Northwest, Everett WA, August 1996.
430. Cancer Pain Management and the AHCPR Guidelines. Arizona State Cancer Pain Initiative, Tempe AZ, August 1996.
431. Pharmaceutical Care in Pain Relief, Symposium on Treatment of the Terminally Ill, World Pharmacy Congress, International Pharmaceutical Federation, Jerusalem Israel, September 1996.
432. Pharmacological Principles of Cancer Pain Management, Wyoming Medical Center and Wyoming Cancer Pain Coalition Education program, Casper WY October 1996.
433. Cancer Pain Management, National Invitational Pharmacists Pain Meeting, Fort Lauderdale FL, October 1996.
434. The Role of Opioids in Cancer Pain, American Academy of Osteopathic Internists 56th Annual Convention and Scientific Sessions, San Francisco CA, October 1996.
435. Opioid use in Chronic Nonmalignant Pain. Advances in the Management of Pain in the Acute and Chronic Setting. University of Utah School of Medicine, Salt Lake City UT October 1996.
436. Pathophysiology of Pain and the Management of AIDS and HIV Pain. Cancer pain Management Conference. Wyoming Medical Center, Casper WY, October 1996.
437. Drug Therapy of Neuropathic Pain. Symposium on Managing Pain: Managing Costs, held in conjunction with the American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans LA, December, 1996.
438. Differentiation and Management of Acute, Chronic Malignant and Chronic Nonmalignant Pain, Pharmacy Corporation of America National Teleconference, January 1997.
439. Pharmacotherapeutics Case Studies. Utah Academy of Physician Assistants 1997 Recertification Review Course, Park City UT, January 1997.
440. Nonopioid and Adjunctive medications. American Academy of Pain Medicine Review Course, Scottsdale AZ, February 1997.
440. Differentiating and Managing Chronic Pain. Frontiers in Pharmacy, El Paso Area Society of Health-System Pharmacists, El Paso TX, March 1997.
441. Cancer Pain Management. National Invitational Meeting of Pain Management Pharmacists, San Antonio TX, April 1997.
442. Oxycodone Analgesia. Invitational Meeting of European Palliative Care Physicians, New York NY, April 1997.
443. Differentiating and Managing Pain in Primary Care. University of Montana School of Pharmacy and Rocky Mountain College Physician Assistant Program Continuing Education Symposium, Billings MT, April 1997.
444. New Findings in the Management of Nonmalignant pain. Medical University of South Carolina New Drug Update, Charleston SC, May 1997.
445. Pain Management Opportunities and Challenges, Invitational Physicians Meeting, New Orleans LA, May 1997.
446. Acute Pain Management Issues, Symposium on Cost-Effective Management of Acute Pain held in conjunction with the American Society of Health-Systems Pharmacists Annual Meeting, Minneapolis MN, June 1997.
447. Pharmacological Issues in Pain Management. Connecticut Hospital Association Interprofessional Education Program., Cromwell CT, June 1997.
448. Cancer Pain Management. Tumor Board Conference, University of Arkansas for the Health Sciences, Little Rock AR, June 1997.
449. Chronic Pain: Differentiating and Managing Chronic Malignant and Chronic Nonmalignant Pain. University Learning Systems, Kauai HI, July 1997.

-continued-

PKY183266034

INVITED PRESENTATIONS (continued)

450. Immunizations: Current Recommendations in Disease Prevention and Management. University Learning Systems, Kauai HI, July 1997.
451. Management of Chronic Nonmalignant Pain in Renally Impaired Patients. St Francis Medical Center, Honolulu HA, July 1997.
452. Pharmacological Advances in Neuropathic Pain Management. McKay Dee Hospital Center, Ogden UT, July 1997.
453. Differentiating and Managing Chronic Pain in Older Patients, Auburn University School of Pharmacy, Gulf Shores AL, July 1997 and Lake Guntersville AL, August 1997.
454. Contemporary Themes in Cancer Pain Management. American Society of Health System Pharmacist Home Care '97 Meeting, Reno NV, August 1997
455. Pain. Washington State Hospice Organization Fall Conference, Feral Way WA, September, 1997
456. Pharmacology in Pain and Symptom Control. Sandia Hospice, Albuquerque NM, September, 1997
457. Management of Chronic Pain Syndromes, Lovelace Health Systems, Albuquerque NM, September 1997.
459. Pain Management and Controlled Substance Prescribing. National Association of boards of Pharmacy/American Association of Colleges of Pharmacy District IV Annual Meeting, Detroit MI, November, 1997.
460. Pain Management in the Long Term Care Setting. American Society of Consultant Pharmacists 25th Annual Meeting, Philadelphia PA, November 1997.
461. The Management of Chronic Malignant Pain. South Carolina Society of Health-System Pharmacists and University of South Carolina, Winter Seminar, Greenville SC, November 1997.
462. Pain and Palliative Care Case Studies. Utah Academy of Physician Assistants Annual Review Course, Park City UT January 1998.
463. Chronic Pain. Utah Academy of Family Physicians, Park City UT, February 1998.
464. Pharmaceutical Care of Patients with Chronic Pain. Northeast Florida Society of Health-system Pharmacists, Jacksonville FL March 1998.
465. Advances in Pain Management. American College of Rheumatology Spring Meeting, Scottsdale AZ, April 1998.
466. Pharmacology of Opioids. Intermountain West Chapter, American Society of Pain Management Nurses Program on Health Care Providers Advocating for Pain Management, Salt Lake City Utah, April 1998.
467. Current Controversies in Managing Chronic Pain. American College of Clinical Pharmacy Practice and Research Spring Forum. Palm Springs CA, April 1998.
468. Pharmacological Management of Neuropathic Pain. Western Pain Society Annual Meeting, San Diego CA, May 1998.
469. Evidence-based Use of Opioids in Pharmaceutical Care. United Kingdom Clinical Pharmacy Association Spring Meeting, Leeds, England, May 1998.
470. Chronic Pain Management. Utah Academy of Family Physicians, Park City UT, February 1998.
471. Pharmaceutical Care of Patients with Chronic Pain. Northeast Florida Society of Health-system Pharmacists, Jacksonville FL March 1998.
472. Advances in Pain Management. American College of Rheumatology Spring Meeting, Scottsdale AZ, April 1998. Pharmacology of Opioids Intermountain West Chapter, American Society of Pain Management Nurses Program on Health Care Providers Advocating for Pain Management, Salt Lake City Utah, April 1998.
473. Pharmacological Management of Neuropathic Pain. Western Pain Society Annual Meeting, San Diego CA, May 1998.
474. Evidence-based Use of Opioids in Pharmaceutical Care. United Kingdom Clinical Pharmacy Association Spring Meeting, Leeds, England, May 1998.
475. Pain Management in Primary Care. American Academy of Physician Assistants Annual Meeting. Salt Lake City UT May 1998.
476. Neuropathic Pain Pathophysiology and Management. American Alliance of Cancer Pain Initiatives Annual Meeting, Portland ME, June 1998.
477. Pain and Symptom Control in Palliative Care. Lovelace Clinic Continuing Education Program. Albuquerque MN, June 1998.
478. Evidence-based Medicine in Palliative Care. Pallyup Hospice, Pallyup WA, July, 1998
479. Effective Use of the Federal Acute and Cancer Pain Management Clinical Practice Guidelines Seattle Veterans Affairs Medical Center, Seattle WA, July 1998.
480. Pharmaceutical Care for Pain. Washington Society of Health-system Pharmacists, Seattle WA, July 1998

-continued-

INVITED PRESENTATIONS (continued)

481. New Trends in the Treatment of Cancer Pain of Cancer Pain. 17th International Cancer Congress, Rio de Janeiro, Brazil, August, 1998.
482. Opioid Pharmacology, Pain Management Update Symposium, Memorial Hospital, Colorado Springs CO, September 1998.
483. Problem-based, Case-oriented Management of Neuropathic Pain. American Pain Society 17th Annual Scientific Meeting, San Diego CA, October 1998.
484. The Rationale Behind the AAPM-APS Consensus Statement on Opioids for the Treatment of Chronic Pain: A Blending of Science and Politics, American Pain Society 17th Annual Scientific Meeting, San Diego CA, October 1998.
485. Neuropathic Pain Management. Pharmacotherapy of neurological disorders Ednet Program, University of Utah College of Pharmacy, Salt Lake City UT, October 1998.
486. National Conference for Nurse Practitioners, Baltimore MD, November 1998.
487. Pain and Symptom Control in Chronic Disease at End-of-life. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998.
488. Pain Management in Arthritis. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998.
489. Refuting Opioid Mythology. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998.
490. COX-2 Inhibitors in the Management of Inflammatory Pain. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998.
491. Anticonvulsants in Neuropathic Pain. Neurology-Psychiatry Continuing Medical Education Program, Park City UT, Dec 1998.
492. Pharmacotherapy for Chronic Pain. Utah Academy of Physician Assistants 1997 Recertification Review Course, Park City UT, January 1999.
493. Pain Management in Long Term Care. Merck Long Term Care Meeting, Salt Lake City UT, February 1999.
494. The Management of Chronic Nonmalignant Pain in the Long Term Care Resident. NeighborCare, Plymouth Meeting PA, March 1999.
495. Rational Opioid Use in End of Life Care. The University of Arkansas for Medical Sciences Palliative Care Faculty Lecture Series. Little Rock AR, March 1999.
496. Pain and Symptom Management in Palliative Care. California Society of Health-System Pharmacists, Focus-'99. San Diego CA, March 1999.
497. Defining and Refuting Myths About Opioid Analgesia. American Association of Pain Management Nurses-Intermountain West Chapter, April 1999.-continued-
498. New Opportunities in the Treatment of Severe Pain. Symposium at the 22nd Annual Meeting of the Scandinavian Association for the Study of Pain. Reykjavik Iceland April 1999.
499. Pharmaceutical Care of the Acute Pain Patient. North Coast Society of Health-System Pharmacists, Santa Rosa CA, May 1999.
500. Pain Management is a Team Game. Southwest Regional Continuing Education Seminar, Indian Health Service, U.S. Public Health Service, Phoenix AZ, June 1999.
501. Nontraditional Analgesics for the Management of Neuropathic Cancer pain. The 10th national Meeting for State Cancer Pain Initiatives, American Alliance of Cancer Pain Initiatives, Salt Lake City UT, June 1999.
502. Clinical Advancements in the Management of Pain. American College of Apothecaries Annual Conference, Kansas City MO, September 1999.
503. Clinical Relevance of Opioid Pharmacokinetics and Metabolism, Symposium held at the American Pain Society 18th Annual Scientific Meeting, Fort Lauderdale FL, October 1999.
504. Oxycodone pharmacokinetics and pharmacodynamics. Pain Symposium, Stockholm, Sweden, October 1999.
505. Neuropathic Pain Management. Advances in End of Life Care, California Geriatric Education Center, University of California at Los Angeles, Woodland Hills CA, November 1999.
506. Pharmacological Treatment Options in Pain Management, Strategies for Pain Management in New Century, Baylor University Medical Center, Dallas TX, November, 1999.

-continued-

PKY183266036

INVITED PRESENTATIONS (continued)

507. Implications of the new JCAHO Pain Standards, American Society of Health-system Pharmacists 34th Annual Midyear Clinical Meeting, Orlando FL, December, 1999.
508. Cancer Pain Management. Radiation Oncology Resident Conference, University of Florida Shands Teaching Hospital, Gainesville FL, December 1999.
509. Pain and Symptom Management in Palliative Care. Northern California Hospice Programs, Kaiser Permanente, Oakland CA, December 1999.
510. Pain Management and Palliative Care, 6th Annual Recertification Review Course, Utah Academy of Physician Assistants, Salt Lake City UT, January 2000
511. Cancer Pain Management. good Samaritan Hospital, Phoenix Arizona, March 2000
512. Pharmaceutical Care of the Pain Patient. Seminar by the Sea, University of Rhode Island College of Pharmacy, Newport RI, March 2000
513. Myths about Opioids. Magic Valley Pharmaceutical Association, Twin Falls Idaho, April 2000
514. Pain Models and Analgesic Pharmacology. Certificate Program in Pain Management, American College of Apothecaries, Coronado CA, May 2000
515. Closing the Gap Between Current Practice and Knowledge in Pain Management. Internal Medicine Grand Rounds, Providence Hospital and Medical Center, Southfield MI, May 2000
516. Empowering Professionals and Patients to Improve Palliative Care, Southwest Florida Regional Medical Center, Fort Myers FL, May 2000
517. Myths and Facts about Opioid Analgesics. Sarasota Memorial Hospital, Sarasota FL, May 2000.
518. Differentiating and Managing Headaches, U.S. Public Health Service, Indian Health Service, Southwest Pharmacy Continuing Education Seminar, Scottsdale AZ, June 2000.
519. Common Opioid Myths, U.S. Public Health Service, Indian Health Service, Southwest Pharmacy Continuing Education Seminar, Scottsdale AZ, June 2000.
520. Nontraditional Analgesics in Cancer Pain Management, American Alliance of Cancer Pain Initiatives, Kansas City MO, June 2000
521. Pain Management in the Community Hospital. Sharp Health Care System, San Diego CA, June 2000
522. Cancer Pain Management - The 5th vital sign for the new Millennium. Hospice Center of Santa Fe, Santa Fe NM, June 2000
523. Management of Chronic Pain in the Elderly, New Mexico Pharmaceutical Association, 71st Annual Convention, Albuquerque NM, June 2000.
524. Opioid Pain Management. Worldwide Pain Conference, World Society of Pain Clinicians, San Francisco CA, July 2000.
525. Is Age a Consideration in Opioid Therapy? Worldwide Pain Conference, World Society of Pain Clinicians, San Francisco CA, July 2000
526. The Management of Chronic Nonmalignant Pain. National Association of Boards of Pharmacy-American Association of Colleges of Pharmacy District 5 63rd Annual Meeting, Winnipeg Manitoba Canada August 2000.
527. Rational and Legal Use of Opioids in Chronic Pain. Garfield Memorial Hospital, Panguitch UT; Bear River Valley Hospital, Tremonton UT; Filmore Community Hospital, Filmore UT; Sanpete Community Hospital, Mt. Pleasant UT, August 2000.
528. Acute and Chronic Pain Medications- How to Decide Which to choose. Atlanta Academy of Institutional Pharmacists, Atlanta GA, August 2000.
529. Pain Management in Long Term Care. Western Medical Directors Association, Salt Lake City UT August, 2000.
530. Acute and Chronic Pain Management, Colegios Farmaceuticos de Puerto Rico, Rio Grande, Puerto Rico, August, 2000
531. Update and Dilemmas in Pain Management and Palliative Pharmaceutical Care. Carolina Seminar. North Carolina Association of Pharmacists and the University of North Carolina and Campbell University Schools of Pharmacy, Greensboro NC, October 2000.
532. Pharmacotherapy of Pain, Clarian Health Partners, Indianapolis IN, October 2000.
533. Pharmacists Role in Pain Management, Indiana College of Clinical Pharmacy, Indianapolis IN, October, 2000.
534. Clinical Use of COX-2 Inhibitors, 109th Annual Convention, Utah Pharmaceutical Association, St. George, UT, May 2001.
535. Myths and Facts about Opioids. 109th Annual Convention, Utah Pharmaceutical Association, St. George, UT, May 2001 .

-continued-

PKY183266037

INVITED PRESENTATIONS (continued)

536. Pain Management in 2001: The Imperative and the Challenges. Pain Management Update. Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Jamaica NY, June 2001.
537. Arthritis Pain Management Guidelines. Pri-Med Mid West Conference, University of Wisconsin-Madison School of Medicine, Rosemont IL, June 2001.
538. Pharmacological Management of Neuropathic Pain in Primary Care, Nurse Practitioner Symposium, University of Colorado School of Nursing. Keystone CO, July 2001
539. The Societal and JCAHO Mandate for Improved Pain Management. Scripps Memorial Hospital Medicine Grand Rounds, La Jolla CA, August 2001
540. Pain Management following Surgery and Trauma. Central Florida Podiatry Association, Orlando FL, September 2001.
541. Opioid Pharmacology: Common Myths and Facts. Pain Grand Rounds. M.D. Anderson Cancer Center and Sand Lake Hospital, Orlando Regional Health Care, Orlando FL, September, 2001.
542. Pain Management: A Mandate for Our Patients. Utah Nurses Association Annual Convention, Salt Lake City UT, September 2001.
543. New and Emerging Agents in Pain Management. Academy of Managed Care Pharmacy, Dallas TX, October, 2001.
544. Opioid Analgesics for Arthritic Pain. Symposium on Pain in Chronic Rheumatoid Disease. American College of Rheumatology Annual Meeting, San Francisco CA, November 2001.
545. The American Pain Society Arthritis Pain Management Guidelines. 36th Midyear Clinical Meeting, American Society of Health-System Pharmacists, New Orleans LA, December, 2001.
546. Evidence-Based Symptom Management in End-of-Life Care. Pain and Palliative Care Grand Rounds, University of Utah Health Sciences Center, Salt Lake City UT, January 2002.
547. Characterization and Management of Neuropathic Pain in Renal Disease. American Nephrology Nurses' Association Management/Advanced Practice Seminar, San Diego CA, January 2002.
548. Pain Management Procedures. Politics and Perceptions. American Society of Pain Management Nurses 2002 Annual Meeting. Salt Lake City UT, March 2002.
549. Safe and Legal Prescribing of Opioids. Oregon Pain Society 3rd Annual meeting. Eugene OR, April, 2002
550. Managing Acute and Chronic Pain. OSF St Francis Medical Center Pain Forum, Peoria IL. May, 2002
551. Evidence-Based Symptom Control. Indian Health Service Palliative Care Program, Albuquerque NM, May 2002.
552. Evidence-Based Medicine: NSAIDs in the management of Pain. McGill University and Université de Montréal, Montreal, Canada, May, 2002.
553. Identifying and Managing Neuropathic Pain. Medical Grand Rounds, Rosemont-Maisonnette Hospital, Montreal, Quebec, Canada. May 2002.
554. Clinical Practice Guideline for Arthritis Pain Management. Laurentian Rheumatology Conference. Mont Tremblant, Quebec, Canada, May 2002.
555. American Pain Society Guideline for Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis Pain Management. Canadian Pain Society 2002 Annual Conference, Winnipeg, Manitoba Canada, May 2002.
556. Neuropathic Pain Management. Kaiser- Permanente Medical Conference, Woodland Hills CA, May 2002.
557. Differentiating and Managing Chronic Myofascial and Neuropathic Pain. Indian Health Service, USPHS. Physician Assistant, Nurse Practitioner, and Pharmacist Annual Continuing Education Programs, Scottsdale AZ. June 2002.
558. Principles of Pain Management. Arizona Society of Health-System Pharmacists and Arizona Pharmacy Association. 2nd Annual Joint Meeting, Litchfield Park AZ, June 2002.
559. Management of neuropathic Pain in the Primary Care Setting. Nurse Practitioner Symposium, University of Colorado health Sciences Center, Keystone CO, July 2002.
560. COX-2 Selective NSAIDs: New therapeutic Options. AmerisourceBergen Annual Meeting, Las Vegas NV, July 2002.
561. Evidence-based Pain Management Guidelines. Grand Rounds. Wyoming Medical Center, Casper WY, September 2002.
561. COX-2 Selective NSAID Analgesia in Inflammatory Pain. Pharmacy Conference. University of Ottawa Health System, Ottawa, Ontario, Canada, September 2002.
562. Arthritis Pain Guideline. Internal Medicine Grand Rounds, University of Utah Hospitals and Clinics. Salt Lake City UT September 2002.
563. Evidence-based Guidelines for the Management of Arthritis Pain. Rheumatology Rounds. Medical University of South Carolina, Charleston, SC, October 2002
564. COX-2 Selective NSAID Therapy for Arthritis Pain. Academy of Managed Care Pharmacy Annual Meeting. Washington DC, October 2002.
565. Transdisciplinary End-of-Life Care. Arizona Hospice and Palliative Care Organization Annual Meeting, Sun City AZ, October 2002.

PKY183266038

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER
 IN COMMONWEALTH OF KENTUCKY, EX REL. JACK CONWAY, ATTORNEY GENERAL v. PURDUE PHARMA L.P., ET AL.,
 CIVIL ACTION NO. 07-CI-OI 303 (PIKE COUNTY CIRCUIT COURT)

P-27120 _ 00061

COMMUNITY ACTIVITIES
Boy Scouts of America

Navajoland District - Kit Carson Council, Tuba City, Arizona	
Assistant Scoutmaster, Troop 572	1968-69
Scoutmaster, Troop 572	1969-70
Quinnipiac Council (New Haven County) Connecticut	
Leadership Training Committee	1973-74
North District - Quinnipiac Council	
Neighborhood Commissioner	1970-71
District Training Chairman	1971-72, 73-74
Unit Commissioner	1972-73
Assistant District Commissioner	1973-74, 74-75
Eli Whitney District - Quinnipiac Council	
Nominating Committee	1975
Assistant District Commissioner	1975-76
District Commissioner	1976-77
Health Careers Explorer Post Committee	1976-77
Yale-New Haven Medical Center	
Great Salt Lake Council, Utah	
Cubmaster, Pack 351	2001- present
Committee Chairman, Troop 351	1993- 2000, 2002-present
Scoutmaster, Troop 351	1987-1993
Varsity Scout Committee	1978-80
New Unit Committee	1978-80
Council Scout Roundtable Commissioner	1981
Council Scout Commissioner	1981-83
Council Relationships Executive Committee	1982-83
College of Commissioner Science Faculty	1983-1988
Dean	1983
Doctoral Dean	1984
Wood Badge Staff	1985, 1986, 1988, 1992
Assistant Chapter Advisor, Order of the Arrow	1989-1991
Shadow Mountain District - Great Salt Lake Council	
District Chairman	1983-86
East Millcreek District - Great Salt Lake Council	
Nominating Committee	2002-
National Jewish Committee on Scouting	1988-present
Subcommittee on Membership	1988-1995
Relationships Division Staff, National Jamboree	1989
Area Coordinator	1993-present
Chair, Long Range Planning Subcommittee	1995-1997
Executive Committee	1995-present
Chair, Program Resources Subcommittee	1997-2001
Vice Chairman	2000-2001
<u>Temple Beth David, Cheshire, Connecticut</u>	
Board of Trustees	1973-74
Ritual Committee	1973-74, 74-75, 76-77
Pulpit Committee, Chair	1973-74
<u>Congregation Kol Ami (Salt Lake City, Utah)</u>	
Adult Education Committee	1977-83, 1990-1991
Chair	1980-82
Religious School Curriculum Committee	1978
Congregation Grant Committee, Chairman	1979-80
Board of Trustees	1979-84
Pulpit Committee	1980-81
Religious Practices Committee	1989-1999, 2001-2002

COMMUNITY ACTIVITIES (continued)

United Jewish Council of Salt Lake / Salt Lake Jewish Federation

Young Leadership Development Group Chairman	1978-80
Campaign Cabinet	1979-80, 1984-1992
Chairman	1983
Board of Directors	1979-83
Vice President	1981-83
Long Range Planning Committee	1990-1993

Community Health Care Plan, Incorporated Health Maintenance Organization

New Haven, Connecticut	
Board of Directors	1974-77
Subcommittee on Nominations and Elections	1974-76
Subcommittee on Dental Services	1975
Subcommittee on Quality Assurance and Clinical Activities	1976-77

Hospice, Incorporated (New Haven, Connecticut)

Evaluative Research Steering Committee	1975-77
Patient Care Task Force	1971-72, 72-73, 73-74
Research Task Force	1973-75
Staff Selection Committee	1971-77

Hospice of Salt Lake

Pharmacological Consultant	1977-94
Board of Directors	1980-82
Chairman, Research and Quality Assurance Committee	1980-82
Vice President (President-Elect)	1981-82
President	1982-83

Community Nursing Service (Salt Lake City)

Pharmacological Consultant	1982-93
Board of Trustees	1982-85
Hospice Advisory Committee	1983-94
Chairman	1983-85, 88-89

Vista Hospice Care Foundation

National Advisory Board	1996-present
Chairman	1996-1999

American Cancer Society, Utah Division

Board of Directors	1980-99
Executive Committee	1986-88
Professional Education Committee	1986-96
Vice Chairman	1984-86
Chairman	1986-88
Think Tank	1991-93
Chairman	1992-93
Strategic Planning Task Force, chairman	1993-94
Division Organization Committee	1995

Utah Cancer Pain Initiative - Cancer Pain Relief-Utah

Steering Committee, Co-Chairman	1991-93
Bylaws Committee	1992-93
Member, Board of Directors	1993-present
Vice President	1993-94
Newsletter editor	1994-1995
President	1995
Role Model Program Planning Committee, Chair	1996